<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:f723b134-302e-4f33-8a8d-df341e6a5f94"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="cdc4f992-b18a-4840-82f3-483ac243cd5c"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-20T11:17:57Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:e76f5baf-85c2-434b-852e-9ffce0250847"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="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"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p><b><span lang="EN-GB" style='font-size:16.0pt;font-family:"Arial",sans-serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:16.0pt;font-family:"Arial",sans-serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Kalydeco 150 mg filmcoated tablets</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Each filmcoated tablet contains 150 mg of ivacaftor.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Excipient with known effect</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Each filmcoated tablet contains 167.2 mg of lactose monohydrate.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none"><span lang="EN-GB">Filmcoated tablet (tablet)</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Light blue, capsuleshaped filmcoated tablets, printed with V 150 in black ink on one side and plain on the other</span><span lang="EN-GB"> (16.5 mm x 8.4 mm in modified tablet shape).</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Kalydeco tablets are indicated: </span></p><p class="labeltext" style="margin-left:28.35pt;text-indent:-.25in"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an <i>R117H CFTR</i> mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (<i>CFTR)</i> gene: <i>G551D</i>, <i>G1244E</i>, <i>G1349D</i>, <i>G178R</i>, <i>G551S</i>, <i>S1251N</i>, <i>S1255P</i>, <i>S549N</i> or <i>S549R</i> (see sections 4.4 and 5.1).</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-align:justify;text-justify: inter-ideograph;line-height:normal;text-autospace:none"> </p><p class="MsoListParagraph" style="margin-left:28.35pt;text-indent:-.25in; text-autospace:none"><span style="font-family:Symbol"></span>In a combination regimen with tezacaftor 100 mg/ivacaftor 150 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who are homozygous for the <i>F508del </i>mutation or who are heterozygous for the <i>F508del</i> mutation and have one of the following mutations in the <i>CFTR</i> gene: <i>P67L, R117C, L206W, R352Q, A455E, D579G, 711+3AG, S945L, S977F, R1070W, D1152H, 2789+5GA, 327226AG, </i>and<i> 3849+10kbCT</i>.</p><p class="MsoNormal" style="margin-left:28.35pt;line-height:normal;text-autospace: none"></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-.25in; text-autospace:none"><a name="_Hlk36013910"><span style="font-family:Symbol"></span>In a combination regimen with ivacaftor 75 mg/tezacaftor 50 mg/elexacaftor 100 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who are homozygous for the <i>F508del</i> mutation in the <i>CFTR</i> gene or heterozygous for <i>F508del</i> in the <i>CFTR</i> gene with a minimal function (MF) mutation (see section 5.1).</a></p><p class="MsoListParagraphCxSpLast"> </p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. If the patient's genotype is unknown, an accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in the <i>CFTR</i> gene (see section 4.1). The phase of the polyT variant identified with the <i>R117H</i> mutation should be determined in accordance with local clinical recommendations.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none"><a name="paragraph00000061"></a></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">Adults</span><span style="font-size:11.0pt">, adolescents and children aged 6 years and older </span><span style="font-size:11.0pt">should be dosed according to Table 1. </span></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span style="font-size:11.0pt">Table 1: Dosing recommendations</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="margin-left:-.25pt;border-collapse:collapse;border:none" width="626"> <tr style="height:16.25pt"> <td style="width:113.4pt;border:solid windowtext 1.0pt;padding:   0in 5.4pt 0in 5.4pt;height:16.25pt" width="151"> <p class="labeltext" style="page-break-after:avoid"></p> </td> <td style="width:233.9pt;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="312"> <p align="center" class="labeltext" style="text-align:center;page-break-after:   avoid"><b><span style="font-size:11.0pt">Morning</span></b></p> </td> <td style="width:122.3pt;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="163"> <p align="center" class="labeltext" style="text-align:center;page-break-after:   avoid"><b><span style="font-size:11.0pt">Evening</span></b></p> </td> </tr> <tr style="height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span style="font-size:   11.0pt">Ivacaftor as monotherapy</span></b></p> </td> </tr> <tr style="height:16.25pt"> <td style="width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="151"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">6 years and older, 25 kg</span></p> </td> <td style="width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">One ivacaftor 150 mg tablet</span></p> </td> <td style="width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="163"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">One ivacaftor 150 mg tablet</span></p> </td> </tr> <tr style="height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span style="font-size:   11.0pt">Ivacaftor in combination with tezacaftor/ivacaftor</span></b></p> </td> </tr> <tr style="height:15.3pt"> <td style="width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="151"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">12 years and older</span></p> </td> <td style="width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">One tezacaftor 100 mg/ivacaftor 150 mg tablet</span></p> </td> <td style="width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="163"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">One ivacaftor 150 mg tablet</span></p> </td> </tr> <tr style="height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span style="font-size:   11.0pt">Ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor</span></b></p> </td> </tr> <tr style="height:15.3pt"> <td style="width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="151"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">12 years and older</span></p> </td> <td style="width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">Two ivacaftor 75 mg/tezacaftor 50 mg/elexacaftor 100 mg   tablets</span></p> </td> <td style="width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="163"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">One ivacaftor 150 mg tablet</span></p> </td> </tr> </table><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid">The <span style="font-size: 11.0pt">morning and evening dose should be taken approximately 12 hours apart with fat-containing food (see Method of administration).</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><i><span style="font-size: 11.0pt">Missed dose</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">If 6 hours or less have passed since the missed morning or evening dose, the patient should take it as soon as possible and continue on the original schedule. If more than 6 hours have passed since the time the dose is usually taken, the patient should be told to wait until the next scheduled dose.</span></p><p class="labeltext"></p><p class="labeltext"><span style="font-size:11.0pt">Patients receiving ivacaftor in a combination regimen should not take more than one dose of either medicine at the same time.</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Concomitant use of CYP3A inhibitors</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">When co-administered with moderate or strong inhibitors of CYP3A, either as monotherapy or</span> in a combination regimen with tezacaftor/ivacaftor<span lang="EN-GB" style="font-size:11.0pt"> or ivacaftor/tezacaftor/elexacaftor</span><span lang="EN-GB" style="font-size:11.0pt">, the dose </span><span lang="EN-GB" style="font-size:11.0pt">should be reduced (see Table 2 for the recommended dose). Dosing intervals</span><span lang="EN-GB" style="font-size:11.0pt"> should be </span><span lang="EN-GB" style="font-size:11.0pt">modified</span><span lang="EN-GB" style="font-size:11.0pt"> according to </span><span lang="EN-GB" style="font-size:11.0pt">clinical response and tolerability (see sections</span><span lang="EN-GB" style="font-size:11.0pt"> 4.4 and 4.5).</span></p><p class="labeltext"> </p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span style="font-size:11.0pt">Table 2: Dosing recommendations for concomitant use with moderate or strong CYP3A inhibitors</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="border-collapse:collapse;border:none"> <thead> <tr> <td style="width:40.25pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="54"> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> <td style="width:215.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="288"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB" style="font-size:10.0pt">Moderate CYP3A inhibitors</span></b></p> </td> <td style="width:197.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="264"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB" style="font-size:10.0pt">Strong CYP3A inhibitors</span></b></p> </td> </tr> </thead> <tr> <td colspan="3" style="width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="605"> <p class="MsoNormal"><b><span lang="EN-GB" style="font-size:10.0pt">Ivacaftor as   monotherapy</span></b></p> </td> </tr> <tr> <td style="width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="54"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">6 years and   older,<br/>   25 kg</span></p> </td> <td style="width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="288"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">One morning tablet   of ivacaftor 150 mg once daily. </span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> <td style="width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="264"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">One morning tablet   of ivacaftor 150 mg twice a week, approximately 3 to 4 days apart.</span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> </tr> <tr> <td colspan="3" style="width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="605"> <p class="MsoNormal"><b><span lang="EN-GB" style="font-size:10.0pt">Ivacaftor in a   combination regimen with tezacaftor/ivacaftor</span></b></p> </td> </tr> <tr> <td style="width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="54"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">12 years   and older</span></p> </td> <td style="width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="288"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">Alternate each morning:</span></p> <p class="MsoListParagraphCxSpFirst" style="margin-left:20.5pt;text-indent:   -.25in"><span style="font-size:10.0pt">-</span><span style="font-size:10.0pt">one tablet of tezacaftor 100 mg/ivacaftor 150 mg   on the first day</span></p> <p class="MsoListParagraphCxSpLast" style="margin-left:20.5pt;text-indent:-.25in"><span style="font-size:10.0pt">-</span><span style="font-size:10.0pt">one tablet of ivacaftor 150 mg   on the next day</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB" style="font-size:10.0pt">Continue alternating tablets each day.</span></p> <p class="MsoNormal" style="margin-left:2.5pt"></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> <td style="width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="264"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">One morning tablet   of tezacaftor 100 mg/ivacaftor 150 mg twice a week, approximately 3   to 4 days apart.</span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> </tr> <tr> <td colspan="3" style="width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="605"> <p class="MsoNormal"><b><span lang="EN-GB" style="font-size:10.0pt">Ivacaftor in   a combination regimen with ivacaftor/tezacaftor/elexacaftor</span></b></p> </td> </tr> <tr> <td style="width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="54"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">12 years   and older</span></p> </td> <td style="width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="288"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">Alternate each morning:   </span></p> <p class="MsoListParagraphCxSpFirst" style="margin-left:20.5pt;text-indent:   -.25in"><span style="font-size:10.0pt">-</span><span style="font-size:10.0pt">two tablets of ivacaftor 75 mg/tezacaftor 50 mg/elexacaftor 100 mg   on the first day </span></p> <p class="MsoListParagraphCxSpLast" style="margin-left:20.5pt;text-indent:-.25in"><span style="font-size:10.0pt">-</span><span style="font-size:10.0pt">one tablet of ivacaftor 150 mg   on the next day </span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB" style="font-size:10.0pt">Continue alternating tablets each day.</span></p> <p class="MsoNormal" style="margin-left:2.5pt"></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> <td style="width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="264"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">Two morning dose   tablets of ivacaftor 75 mg/tezacaftor 50 mg/elexacaftor 100 mg   twice a week, approximately 3 to 4 days apart.</span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> </tr> </table><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Special populations</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal"><i>Elderly</i></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal">Very limited data are available for elderly patients treated with ivacaftor (administered as monotherapy or in a combination regimen). No dose adjustment specific to this patient population is required (see section 5.2).</p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or endstage renal disease (see sections 4.4 and 5.2).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="labeltextheading"><a name="_Hlk46222749"></a><a name="_Hlk45278269"><span lang="EN-GB" style="font-size:11.0pt">Hepatic impairment</span></a></p><p class="labeltextheading"></p><p class="labeltextheading"><span lang="EN-GB" style="font-size:11.0pt;font-style: normal">No dose adjustment is necessary for ivacaftor as monotherapy or in a combination regimen in patients with mild hepatic impairment (ChildPugh Class A). </span></p><p class="labeltextheading"></p><p class="labeltextheading"><span lang="EN-GB" style="font-size:11.0pt;font-style: normal">For patients with moderate hepatic impairment (ChildPugh Class B) </span><span lang="EN-GB" style="font-size:11.0pt;font-style:normal">the dose </span><span lang="EN-GB" style="font-size:11.0pt;font-style:normal">of ivacaftor as monotherapy </span><span lang="EN-GB" style="font-size:11.0pt;font-style:normal">should be reduced </span><span lang="EN-GB" style="font-size:11.0pt;font-style:normal">to 150 mg once daily. </span></p><p class="labeltextheading"></p><p class="labeltextheading"><span lang="EN-GB" style="font-size:11.0pt;font-style: normal">For patients with severe hepatic impairment (Child-Pugh Class C), the dose of ivacaftor as monotherapy should be reduced to 150 mg every other day or less frequently. </span></p><p class="labeltextheading"></p><p class="labeltextheading"><span lang="EN-GB" style="font-size:11.0pt;font-style: normal">For use as an evening dose in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor see Table 3 for dosing regimen</span><span lang="EN-GB" style="font-size:11.0pt;font-style:normal"> recommendations</span><span lang="EN-GB" style="font-size:11.0pt;font-style:normal">. </span></p><p class="labeltextheading" style="page-break-after:auto"></p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span style="font-size:11.0pt;color:black">Table 3: Recommendations for patients with moderate or severe hepatic impairment </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:104.54%;border-collapse:collapse;border:none" width="104%"> <tr> <td style="width:13.42%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="13%"> <p class="MsoNormal"></p> </td> <td style="width:49.26%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="49%"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Moderate (Child-Pugh Class B)</span></b></p> </td> <td style="width:37.32%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="37%"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Severe (Child-Pugh Class C)</span></b></p> </td> </tr> </table><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="border-collapse:collapse;border:none" width="633"> <tr> <td colspan="3" style="width:474.65pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="633"> <p class="MsoNormal"><b><span lang="EN-GB" style="font-size:10.0pt">Ivacaftor as   monotherapy</span></b></p> </td> </tr> <tr> <td style="width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="83"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">6 years and   older,<br/>   25 kg</span></p> </td> <td style="width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="314"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">One morning   tablet of ivacaftor 150 mg once daily. </span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">Use is not   recommended unless the benefits are expected to outweigh the risks. </span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">In such cases,   take one morning tablet of ivacaftor 150 mg every other day or less   frequently. </span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">Dosing interval   should be modified according to clinical response and tolerability. </span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> </tr> <tr> <td colspan="3" style="width:474.65pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="633"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB" style="font-size:10.0pt">Ivacaftor in a combination regimen with   tezacaftor/ivacaftor</span></b></p> </td> </tr> <tr> <td style="width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="83"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:10.0pt">12 years and older</span></p> </td> <td style="width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="314"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:10.0pt">One morning tablet of tezacaftor 100 mg/ivacaftor 150 mg   once daily.</span></p> <p class="MsoNormal" style="page-break-after:avoid"></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:10.0pt">Use is not recommended unless the benefits are   expected to outweigh the risks. </span></p> <p class="MsoNormal" style="page-break-after:avoid"></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:10.0pt">In such cases, take one morning tablet of tezacaftor 100 mg/ivacaftor 150 mg   once daily or less frequently. </span></p> <p class="MsoNormal" style="page-break-after:avoid"></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:10.0pt">Dosing interval should be modified according to   clinical response and tolerability. </span></p> <p class="MsoNormal" style="page-break-after:avoid"></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> </tr> <tr> <td colspan="3" style="width:474.65pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="633"> <p class="MsoNormal"><b><span lang="EN-GB" style="font-size:10.0pt">Ivacaftor in   a combination regimen with ivacaftor/tezacaftor/elexacaftor </span></b></p> </td> </tr> <tr> <td style="width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="83"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">12 years   and older</span></p> </td> <td style="width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="314"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">Use not   recommended.</span></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">Use should only   be considered when there is a clear medical need and the benefits are   expected to outweigh the risks.</span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">If used:   alternate each day between two   ivacaftor 75 mg/tezacaftor 50 mg/elexacaftor 100 mg   tablets and one   ivacaftor 75 mg/tezacaftor 50 mg/elexacaftor 100 mg   tablet.</span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">Should not be   used.</span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No morning   ivacaftor 75 mg/tezacaftor 50 mg/elexacaftor 100 mg dose.</span></p> <p class="MsoNormal"></p> <p class="MsoNormal"><span lang="EN-GB" style="font-size:10.0pt">No evening dose.</span></p> </td> </tr> </table><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The safety and efficacy of ivacaftor monotherapy in children aged less than 4 months have not been established. No data are available.</span></p><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal">An appropriate dose for children under 6 years of age and weighing less than 25 kg cannot be achieved with ivacaftor tablets.</p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Limited data are available in patients less than 6 years of age with an <i>R117H </i>mutation in the <i>CFTR </i>gene. Available data in patients aged </span><span style="font-size:11.0pt">6 years</span><span lang="EN-GB" style="font-size: 11.0pt"> and older are described in sections 4.8, 5.1, and 5.2.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">The safety and efficacy of ivacaftor in a combination regimen with tezacaftor/ivacaftor and ivacaftor/tezacaftor/elexacaftor in children aged less than 12 years have not been established. No data are available.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Method of administration</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">For oral use. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Patients should be instructed to swallow the tablets whole. The tablets should not be chewed, crushed, or broken before swallowing because there are no clinical data currently available to support other methods of administration.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Ivacaftor tablets should be taken with fatcontaining food.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Food or drink containing grapefruit should be avoided during treatment (see section 4.5).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3       Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="labeltext" style="page-break-after:avoid"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4       Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><span lang="EN-GB">Only patients with CF who had a <i>G551D</i>, <i>G1244E</i>, <i>G1349D</i>, <i>G178R</i>, <i>G551S</i>, <i>S1251N</i>, <i>S1255P</i>, <i>S549N</i>, <i>S549R</i> gating (class III), <i>G970R</i> </span>or <i>R117H </i><span lang="EN-GB">mutation in at least one allele of the <i>CFTR</i> gene were included in studies 1, 2, 5 and 6 (see section 5.1).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormalIndent" style="margin:0in"><span lang="EN-GB">In study 5, four patients with the <i>G970R</i> mutation were included. In three of four patients the change in the sweat chloride test was &lt; 5 mmol/L and this group did not demonstrate a clinically relevant improvement in FEV<sub>1</sub> after 8 weeks of treatment. Clinical efficacy in patients with the <i>G970R</i> mutation of the <i>CFTR</i> gene could not be established (see section 5.1).</span></p><p class="MsoNormalIndent" style="margin:0in"></p><p class="MsoNormalIndent" style="margin:0in"><span lang="EN-GB">Efficacy results from a phase 2 study in patients with CF who are homozygous for the <i>F508del </i>mutation in the <i>CFTR</i> gene showed no statistically significant difference in FEV<sub>1</sub> over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1). Therefore, use of ivacaftor as monotherapy in these patients is not recommended.</span></p><p class="MsoNormalIndent" style="margin:0in"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Less evidence of a positive effect of ivacaftor has been shown for patients with an <i>R117H7T</i> mutation associated with less severe disease in study 6 (see section 5.1). </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="labeltext"><span style="font-size:11.0pt">Ivacaftor in a combination regimen with tezacaftor/ivacaftor should not be prescribed in patients with CF </span><span style="font-size:11.0pt">who are heterozygous for the <i>F508del</i> mutation and have a second <i>CFTR</i> mutation not listed in section 4.1.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Effect on liver function tests</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><span lang="EN-GB">Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in subjects with CF. Transaminase elevations have been observed in some patients treated with ivacaftor as monotherapy and in combination regimens with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor. Therefore, liver function tests are recommended for all patients prior to initiating ivacaftor, every 3 months during the first year of treatment and annually thereafter. For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. In the event of significant elevations of transaminases (e.g., patients with ALT or AST &gt; 5 x the upper limit of normal (ULN), or ALT or AST &gt; 3 x ULN with bilirubin &gt; 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see section 4.8).</span></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><a name="_Hlk45278421"><u><span lang="EN-GB">Hepatic impairment</span></u></a></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Use of ivacaftor, either as monotherapy or in a combination regimen with tezacaftor/ivacaftor, is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks. Patients with severe hepatic impairment should not be treated with ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor. (See Table 3 and sections 4.2 and 5.2). </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">For patients with moderate hepatic impairment, use of ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor is not recommended. Treatment should only be considered when there is a clear medical need and the benefits are expected to outweigh the risks. If used, it should be used with caution at a reduced dose (see Table 3 and sections 4.2 and 5.2).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Renal impairment</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Caution is recommended while using ivacaftor, </span><span style="font-size:11.0pt">either as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor,</span><span lang="EN-GB" style="font-size:11.0pt"> in patients with severe renal impairment or endstage renal disease (see sections 4.2 and 5.2).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Patients after organ transplantation</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ivacaftor, either as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor, has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with ciclosporin or tacrolimus.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Rash events </span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The incidence of rash events with ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor was higher in females than in males</span>, particularly in females taking hormonal contraceptives<span lang="EN-GB">. A role for hormonal contraceptives in the occurrence of rash cannot be excluded. For patients taking hormonal contraceptives who develop rash, interrupting treatment with ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor and hormonal contraceptives should be considered. Following the resolution of rash, it should be considered if resuming ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor without hormonal contraceptives is appropriate. If rash does not recur, resumption of hormonal contraceptives can be considered (see section 4.8).</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Interactions with medicinal products</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">CYP3A inducers</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Exposure to ivacaftor is significantly decreased and exposures to elexacaftor and tezacaftor are expected to decrease by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, co-administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) with strong CYP3A inducers is not recommended (see section 4.5). </span></p><p class="labeltext"> </p><p class="labeltext" style="page-break-after:avoid"><i><span style="font-size: 11.0pt">CYP3A inhibitors</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">Exposure to ivacaftor, tezacaftor and elexacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) must be adjusted when used concomitantly with strong or moderate CYP3A inhibitors (see Table 2 and sections 4.2 and 4.5).</span></p><p class="labeltext" style="page-break-after:avoid"> </p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Cases of noncongenital lens opacities/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor and ivacaftor-containing regimens. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and followup ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment</span><span lang="EN-GB">, either as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor (see section 5.3).</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Lactose content</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicine.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Sodium content</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodiumfree.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and Pgp and a potential inhibitor of CYP2C9. <i>In vitro</i> studies showed that ivacaftor is not a substrate for Pgp. </span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Medicinal products affecting the pharmacokinetics of ivacaftor, tezacaftor and/or elexacaftor</span></u></p><p class="labeltext" style="page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">CYP3A inducers</span></i></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Coadministration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor. Coadministration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor/</span><span lang="EN-GB" style="font-size:11.0pt">ivacaftor</span><span lang="EN-GB" style="font-size:11.0pt"> or ivacaftor/tezacaftor/elexacaftor</span><span lang="EN-GB" style="font-size:11.0pt">)</span><span lang="EN-GB" style="font-size: 11.0pt"> with strong </span><span lang="EN-GB" style="font-size:11.0pt">CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. Johns wort (<i>Hypericum perforatum</i>), is not recommended (see section 4.4).</span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="MsoCommentText" style="line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">No dose adjustment is recommended when ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) is used with moderate or weak CYP3A inducers. </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">CYP3A inhibitors</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) is recommended for coadministration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see sections 4.2 and 4.4).</span></p><p class="labeltext"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Coadministration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections 4.2 and 4.4).</span></p><p class="labeltext"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Coadministration of ivacaftor with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor, see section 4.2).</span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Potential for ivacaftor to interact with transporters</span></i></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">In vitro</span></i><span lang="EN-GB" style="font-size:11.0pt"> studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP <i>in vitro</i>. Due to its high intrinsic permeability and low likelihood of being excreted intact, co-administration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1IVA, while any potential changes in M6IVA exposures are not expected to be clinically relevant. </span></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Ciprofloxacin</span></i></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Coadministration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) is coadministered with ciprofloxacin.</span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Medicinal products affected by ivacaftor, tezacaftor and/or elexacaftor</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and/or Pgp, and/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.</span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">CYP2C9 substrates</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during coadministration of warfarin with ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor). Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.</span></p><p class="MsoCommentText" style="line-height:normal"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Digoxin and other Pgp substrates</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Coadministration with digoxin, a sensitive Pgp substrate, increased digoxin exposure by 1.3fold, consistent with weak inhibition of Pgp by ivacaftor. Administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) may increase systemic exposure of medicinal products that are sensitive substrates of Pgp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly</span><span style="font-size:11.0pt"> with</span><span lang="EN-GB" style="font-size:11.0pt"> digoxin or other substrates of Pgp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.</span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">CYP3A substrates </span></i></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Coadministration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are coadministered with ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor). </span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Hormonal contraceptives</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) has been studied with an oestrogen/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive. Therefore, no dose adjustment of oral contraceptives is necessary.</span></p><p class="MsoCommentText" style="line-height:normal"></p><p style="margin:0in;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Paediatric population</span></u></p><p style="margin:0in;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p style="margin:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size: 11.0pt">Interaction studies have only been performed in adults.</span></p><p style="margin:0in;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6    Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p style="margin:0in;page-break-after:avoid"></p><p class="labeltext" style="margin-left:28.1pt;text-indent:-28.1pt;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Pregnancy</span></u></p><p class="labeltext" style="margin-left:28.1pt;text-indent:-28.1pt;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women. Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of ivacaftor during pregnancy.</span></p><p class="MsoNormalIndent" style="margin:0in"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Breastfeeding</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">It is unknown whether ivacaftor and/or its metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of ivacaftor into the milk of lactating female rats. As such, a risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from ivacaftor therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</span></p><p class="MsoNormalIndent" style="margin:0in"></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><u><span lang="EN-GB">Fertility</span></u></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3).</span></p><p style="margin:0in"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ivacaftor has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore,</span><span lang="EN-GB"> patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Summary of the safety profile</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">The most common adverse reactions experienced by patients aged 6 years and older who received ivacaftor are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), </span><span lang="EN-GB" style="font-size:11.0pt">dizziness (9.2%), </span><span style="font-size:11.0pt">rash (12.8%</span><span lang="EN-GB" style="font-size: 11.0pt">) and </span><span lang="EN-GB" style="font-size:11.0pt">bacteria</span><span style="font-size:11.0pt">in </span><span style="font-size:11.0pt">sputum (12.8%).</span><span lang="EN-GB" style="font-size:11.0pt">Transaminase elevations occurred in 12.8% of ivacaftor-treated patients versus 11.5% of placebotreated patients.</span></p><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).</span></p><p class="labeltext"></p><p class="labeltext"><span style="font-size:11.0pt">Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).</span></p><p class="labeltext"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><a name="_Hlk45279317"><u><span lang="EN-GB" style="font-size:11.0pt">Tabulated list of adverse reactions</span></u></a></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid">Table 4 reflects the adverse reactions observed with ivacaftor monotherapy in clinical trials (placebo-controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. Additional adverse reactions observed with ivacaftor in a combination regimen with tezacaftor/ivacaftor and/or in a combination regimen with ivacaftor/tezacaftor/elexacaftor are also provided in Table 4. The frequency of adverse reactions is defined as follows: very common ( 1/10); common ( 1/100 to &lt; 1/10); uncommon ( 1/1,000 to &lt; 1/100); rare ( 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). <span lang="EN-GB">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.3pt;text-indent:-40.3pt;line-height:normal;page-break-after: avoid"><b><span lang="EN-GB">Table 4: Adverse reactions in patients treated with ivacaftor monotherapy and/or in a combination regimen</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.18%;margin-left:-.25pt;border-collapse:collapse;border:none" width="99%"> <thead> <tr style="page-break-inside:avoid;height:15.5pt"> <td style="width:34.06%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:15.5pt" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">System organ class</span></b></p> </td> <td style="width:35.94%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt" valign="top" width="35%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB">Adverse reactions</span></b></p> </td> <td style="width:30.0%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt" valign="top" width="30%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB">Frequency</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="4" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Infections and infestations</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Upper respiratory tract infection</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nasopharyngitis</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Influenza </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common </span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Rhinitis</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Metabolism and nutrition disorders</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Hypoglycaemia </span><sup><span lang="EN-GB" style='font-family:   "Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common </span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="2" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Nervous system disorders</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Headache</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Dizziness</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="6" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ear and labyrinth disorders</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ear pain</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Ear discomfort</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Tinnitus</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Tympanic membrane   hyperaemia</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Vestibular   disorder</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Ear congestion</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="7" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Respiratory, thoracic and mediastinal disorders</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Oropharyngeal pain</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nasal   congestion</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Abnormal   breathing </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common </span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Rhinorrhoea </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common </span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Sinus   congestion</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Pharyngeal   erythema</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Wheezing </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="5" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Gastrointestinal disorders</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Abdominal pain</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Diarrhoea</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Abdominal pain   upper </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Flatulence </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common </span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nausea <sup>*</sup></span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="3" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="DA">Hepatobiliary disorders</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Transaminase elevations</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Alanine aminotransferase increased </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Aspartate aminotransferase increased </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common </span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="3" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Rash</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Acne </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Pruritus </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common </span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="5" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Reproductive system and breast disorders</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Breast mass</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Breast   inflammation</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Gynaecomastia</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nipple   disorder</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nipple pain</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td rowspan="3" style="width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Investigations</span></p> </td> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Bacteria in sputum</span></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Blood creatine phosphokinase increased </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.2in"> <td style="width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="35%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Blood pressure increased </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'></span></sup></p> </td> <td style="width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in" valign="top" width="30%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">uncommon </span></p> </td> </tr> </table><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><span lang="EN-GB" style="font-size:9.0pt">*</span><span lang="EN-GB" style="font-size:9.0pt"> Adverse reaction and frequency reported from clinical studies with ivacaftor in combination with tezacaftor/ivacaftor</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style='font-size:9.0pt; font-family:"Arial",sans-serif'></span></sup><span lang="EN-GB" style="font-size:9.0pt"> Adverse reaction and frequency reported from clinical studies with ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Description of selected adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Transaminase elevations </span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">During the 48-week placebocontrolled studies 1 and 2 of ivacaftor as monotherapy in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5 or &gt; 3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftortreated patients and 1.0%, 1.9% and 8.7% in placebotreated patients, respectively. Two patients, one on placebo and one on ivacaftor permanently discontinued treatment for elevated transaminases, each &gt; 8 x ULN. No ivacaftortreated patients experienced a transaminase elevation &gt; 3 x ULN associated with elevated total bilirubin &gt; 1.5 x ULN. In ivacaftortreated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations &gt; 5 x ULN. In all instances where dosing was interrupted for elevated transaminases</span><span lang="EN-GB">and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4).</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">During the placebo controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5, or &gt; 3 x ULN were 0.2%, 1.0%, and 3.4% in tezacaftor/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%) on placebo permanently discontinued treatment for elevated transaminases. No patients treated with tezacaftor/ivacaftor experienced a transaminase elevation &gt;3 x ULN associated with elevated total bilirubin &gt;2 x ULN. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">During the 24-week, placebo-controlled, phase 3 study of ivacaftor/tezacaftor/elexacaftor, these figures were 1.5%, 2.5%, and 7.9% in ivacaftor/tezacaftor/elexacaftor-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor treated patients and 4.0% in placebo-treated patients.</span></p><p class="MsoNormal" style="line-height:normal"> </p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Rash events</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Rash events, generally mild to moderate in severity, have been observed with the use of ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor and occurred more frequently in female-treated patients (16.3%) and in those taking hormonal contraceptives (20.5%). See section 4.4.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Increased creatine phosphokinase </span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Generally transient and asymptomatic increases in </span><span lang="EN-CA">creatine phosphokinase were observed in patients treated with ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor, which did not lead to treatment discontinuation.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Increased blood pressure</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">An increase from baseline in mean systolic and diastolic blood pressure of 3.5 mmHg and 1.9 mmHg, respectively was observed in patients treated with ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The safety data of ivacaftor as monotherapy were evaluated in 6 patients between 4 months to less than 6 months of age, 11 patients between 6 months to less than 12 months of age, </span><span lang="EN-GB">19 patients between 12 months to less than 24 months of age, </span><span lang="EN-GB">34 patients between 2 to less than 6 years of age,</span><span lang="EN-GB">61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The safety profile of ivacaftor (as monotherapy or in a combination regimen) is generally consistent among paediatric patients and is also consistent with adult patients.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The incidence of transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12 years), study 7 (patients aged 2 to less than 6 years), and study 8 (patients </span><span lang="EN-GB">aged 6 to less than </span><span lang="EN-GB">24 months) are described in Table 5. In the placebo controlled studies</span><span lang="EN-GB">, the incidence of transaminase elevations </span><span lang="EN-GB">were similar between treatment with ivacaftor (15.0%)</span><span lang="EN-GB"> and </span><span lang="EN-GB">placebo (14.6%). Across all populations, </span>peak LFT elevations <span lang="EN-GB">returned to baseline levels following interruption, and </span>in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully <span lang="EN-GB">(see section 4.4). </span>Cases suggestive of positive rechallenge were observed<span lang="EN-GB">. In study 7 </span><span lang="EN-GB">ivacaftor was permanently discontinued in one patient. </span><span lang="EN-GB">In study 8 </span><span lang="EN-GB">no patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in either cohort (see section 4.4 for management of elevated transaminases).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-bottom:12.0pt"><b><span lang="EN-GB">Table 5: Transaminase elevations in patients 4 months to &lt; 12 years treated with ivacaftor as monotherapy</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="margin-left:6.85pt;border-collapse:collapse;border:none"> <tr style="height:28.95pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="161"> <p class="MsoNormal"></p> </td> <td style="width:49.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">n</span></b></p> </td> <td style="width:80.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">% of Patients &gt; 3 x ULN </span></b></p> </td> <td style="width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">% of Patients &gt;5 x ULN</span></b></p> </td> <td style="width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">% of Patients &gt; 8 x ULN</span></b></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">6 to &lt;12 years</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">40</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">15.0%   (6)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2.5%   (1)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2.5%   (1)</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">2 to &lt;6 years</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">34</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">14.7%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">14.7%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">14.7%   (5)</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">12 to &lt;24 months</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">18</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">27.8%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11.1%   (2)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11.1%   (2)</span></p> </td> </tr> <tr style="height:13.7pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">6 to &lt;12 months</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">9.1%   (1)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> </tr> <tr style="height:13.7pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">4 to &lt;6 months</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">6</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> </tr> </table><p class="labeltext" style="page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Reporting of suspected adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background: lightgrey">the national reporting system listed in </span></span><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span lang="EN-GB" style="color:windowtext;background:lightgrey">Appendix V</span></a><span lang="EN-GB">.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9       Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Pharmacotherapeutic group: Other respiratory system products, ATC code: </span><span lang="EN-GB">R07AX02</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Mechanism of action</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ivacaftor is a potentiator of the CFTR protein, i.e., <i>in vitro</i> ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channelopen probability compared to normal CFTR. Ivacaftor also potentiated the channelopen probability of R117HCFTR, which has both low channelopen probability (gating) and reduced channel current amplitude (conductance). The <i>G970R </i>mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><i><span lang="EN-GB">In vitro</span></i><span lang="EN-GB"> responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to <i>in vivo </i>pharmacodynamic response (e.g., sweat chloride) or clinical benefit. </span><span lang="EN-GB">The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Pharmacodynamic effects</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor as monotherapy</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">In studies 1 and 2 in patients with the <i>G551D </i>mutation in one allele of the <i>CFTR</i> gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was 48 mmol/L [95% CI 51, 45] and 54 mmol/L [95% CI 62, 47], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="documenttext" style="margin-bottom:0in"><span lang="EN-GB" style="font-size:11.0pt">In study 5, part 1 in patients who had a non<i>G551D</i> gating mutation in the <i>CFTR</i> gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of 49 mmol/L (95% CI 57, 41) through 8 weeks of treatment. However, in patients with the <i>G970R</i><i>CFTR</i> mutation, the mean (SD) absolute change in sweat chloride at week 8 was 6.25 (6.55) mmol/L. Similar results to part 1 were seen in part 2 of the study. </span><span style="font-size:11.0pt">At the 4week followup visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pretreatment levels.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="documenttext" style="margin-bottom:0in"><span lang="EN-GB" style="font-size:11.0pt">In study 6 in patients aged 6 years or older with CF who had an <i>R117H</i> mutation in the <i>CFTR</i> gene, the treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment was 24 mmol/L (95% CI 28, 20). In subgroup analyses by age, the treatment difference was -21.87 mmol/L (95% CI: -26.46, -17.28) in patients aged 18 years or older, and -27.63 mmol/L (95% CI: -37.16, -18.10) in patients aged 6-11 years. </span><span lang="EN-GB" style="font-size:11.0pt">Two patients 12 to 17</span><span lang="EN-GB" style="font-size:11.0pt">years of age were enrolled in this study.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Ivacaftor in a combination regimen with tezacaftor/ivacaftor</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB"><br/> </span></i><span lang="EN-GB">In patients homozygous for the <i>F508del </i>mutation, the treatment difference between ivacaftor in combination with tezacaftor/ivacaftor and placebo in mean absolute change from baseline in sweat chloride through week 24, was 10.1 mmol/L (95% CI: 11.4, 8.8<span style="color:black">).</span></span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In patients heterozygous for the <i>F508del </i>mutation and a second mutation associated with residual CFTRactivity, the treatment difference in mean absolute change from baseline in sweat chloride through week 8 was 9.5 mmol/L (95% CI: 11.7, 7.3) between tezacaftor/ivacaftor and placebo, and 4.5 mmol/L (95% CI: 6.7, 2.3) between ivacaftor and placebo.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="documenttext" style="margin-bottom:0in;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">In patients with an <i>F508del</i> mutation on one allele and a mutation on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor, the treatment difference between ivacaftor/tezacaftor/elexacaftor and placebo for mean absolute change in sweat chloride from baseline through week 24 was 41.8 mmol/L (95% CI: -44.4, -39.3).</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">In patients homozygous for the <i>F508del </i>mutation, the treatment difference between ivacaftor/tezacaftor/elexacaftor and tezacaftor/ivacaftor for mean absolute change in sweat chloride from baseline at week 4 was 45.1 mmol/L (95% CI: -50.1, -40.1).</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="documenttext" style="margin-bottom:0in;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Clinical efficacy and safety</span></u></p><p class="documenttext" style="margin-bottom:0in;page-break-after:avoid"></p><p class="documenttext" style="margin-bottom:0in;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor as monotherapy</span></i></p><p class="documenttext" style="margin-bottom:0in;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB">Study 1 and 2: studies in patients with CF with G551D gating mutations</span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="labeltext" style="margin-right:-1.85pt;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">The efficacy of ivacaftor has been evaluated in two phase 3 randomised, doubleblind, placebocontrolled, multicentre studies of clinically stable patients with CF who had the <i>G551D</i> mutation in the <i>CFTR</i> gene on at least 1 allele and had FEV<sub>1</sub>  40% predicted.</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the <i>F508del</i> mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV<sub>1</sub> was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the <i>F508del</i> mutation in the second allele. At baseline, mean predicted FEV<sub>1</sub> was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV<sub>1</sub> less than 70% predicted at baseline.</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV<sub>1</sub> through 24 weeks of treatment.</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV<sub>1</sub> (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV<sub>1</sub> were rapid in onset (day 15) and durable through 48 weeks.</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week 24 in patients with baseline predicted FEV<sub>1 </sub>greater than 90% in study 2 was 6.9 percentage points (3.8, 17.6).</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">The results for clinically relevant secondary endpoints are shown in Table 6.</span></p><p class="labeltext"></p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="EN-GB" style="font-size:11.0pt">Table 6: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2</span></b></p><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:98.82%;margin-left:5.45pt;border-collapse:collapse" width="98%"> <thead> <tr style="height:10.5pt"> <td rowspan="2" style="width:27.12%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="bottom" width="27%"> <p class="MsoNormal" style="margin-left:55.0pt;line-height:normal;page-break-after:    avoid"><b><span lang="EN-GB">Endpoint</span></b></p> </td> <td colspan="2" style="width:34.82%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="34%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB">Study 1</span></b></p> </td> <td colspan="2" style="width:38.06%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="38%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB">Study 2</span></b></p> </td> </tr> <tr style="height:28.25pt"> <td style="width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Treatment difference<sup>a</sup></span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">(95% CI)</span></b></p> </td> <td style="width:14.64%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><i><span lang="EN-GB">P </span></i><span lang="EN-GB">value</span></b></p> </td> <td style="width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Treatment difference<sup>a</sup></span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">(95% CI)</span></b></p> </td> <td style="width:17.88%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"><b><i><span lang="EN-GB">P </span></i><span lang="EN-GB">value</span></b></p> </td> </tr> </thead> <tr style="height:10.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Mean absolute change from baseline in CFQ-R</span></b><sup><span lang="EN-GB">b</span></sup><b><span lang="EN-GB"> respiratory domain score   (points)</span></b><sup><span lang="EN-GB">c</span></sup></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Through week   24</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">8.1</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(4.7, 11.4)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">6.1</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.4, 13.5)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.1092</span></p> </td> </tr> <tr style="height:18.85pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Through week   48</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">8.6</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(5.3, 11.9)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">5.1</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.6, 11.8)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.1354</span></p> </td> </tr> <tr style="height:9.95pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Relative risk of pulmonary exacerbation</span></b></p> </td> </tr> <tr style="height:10.5pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Through week 24</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.40</span><sup><span lang="EN-GB">d</span></sup></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0016</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">NA</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr style="height:9.95pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Through week 48</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.46<sup>d</sup></span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0012</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">NA</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr style="height:10.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Mean absolute change from baseline in body weight (kg)</span></b></p> </td> </tr> <tr style="height:18.85pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At week   24</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">2.8</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.8, 3.7)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">1.9</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.9, 2.9)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0004</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At week   48</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">2.7</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.3, 4.1)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">2.8</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.3, 4.2)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0002</span></p> </td> </tr> <tr style="height:15.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Mean absolute change from baseline in BMI (kg/m<sup>2</sup>)</span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At week 24</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.94</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.62, 1.26)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.81</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.34, 1.28)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0008</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At week 48</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.93</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.48, 1.38)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">1.09</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.51, 1.67)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0003</span></p> </td> </tr> <tr style="height:15.05pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.05pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Mean change from baseline in zscores</span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Weightforage   zscore at week 48<sup>e</sup></span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.33</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.04, 0.62)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.0260</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.39</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.24, 0.53)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">&lt; 0.0001</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">BMIforage zscore at week 48<sup>e</sup></span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.33</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">(0.002, 0.65)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0490</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.45</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">(0.26, 0.65)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">&lt; 0.0001</span></p> </td> </tr> </table><p class="tablefootnote" style="margin-top:6.0pt;page-break-after:avoid"><span lang="EN-GB" style="font-size:9.0pt">CI: confidence interval; NA: not analysed due to low incidence of events</span></p><p class="tablefootnote" style="margin-left:.2in;text-indent:-.2in;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">a</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Treatment difference = effect of ivacaftor  effect of placebo</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">b</span></sup><span lang="EN-GB" style="font-size:9.0pt">     CFQR: Cystic Fibrosis QuestionnaireRevised is a diseasespecific, healthrelated qualityoflife measure for CF.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">c</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Study 1 data were pooled from CFQR for adults/adolescents and CFQR for children 12 to 13 years of age; Study 2 data were obtained from CFQR for children 6 to 11 years of age.</span></p><p align="left" class="tabletextcenterjustified" style="margin-top:0in;margin-right: 0in;margin-bottom:0in;margin-left:.2in;text-align:left;text-indent:-.2in; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">d</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Hazard ratio for time to first pulmonary exacerbation</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">e</span></sup><span lang="EN-GB" style="font-size:9.0pt">     In subjects under 20 years of age (CDC growth charts)</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB">Study 5: study in patients with CF with nonG551D gating mutations</span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Study 5 was a phase 3, twopart, randomised, doubleblind, placebocontrolled, crossover study (part 1) followed by a 16week openlabel extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a <i>G970R</i> or non<i>G551D</i> gating mutation in the <i>CFTR</i> gene (<i>G178R</i>, <i>S549N</i>, <i>S549R</i>, <i>G551S</i>, <i>G1244E</i>, <i>S1251N</i>, <i>S1255P</i> or <i>G1349D</i>).</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fatcontaining food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4 to 8week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to part 1 placebo/ivacaftor treatment sequence and 16 weeks for patients randomised to part 1 ivacaftor/placebo treatment sequence.</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Thirtynine patients (mean age 23 years) with baseline FEV<sub>1</sub></span><span lang="EN-GB" style="font-size: 11.0pt"> 40% predicted (mean FEV<sub>1</sub> 78% predicted [range: 43% to 119%]) were enrolled. Sixtytwo percent (24/39) of them carried the <i>F508del</i><i>CFTR</i> mutation in the second allele. </span><span style="font-size:11.0pt">A total of 36 patients continued into part 2 (18 per treatment sequence).</span></p><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In part 1 of study 5, the mean FEV<sub>1</sub> percent predicted at baseline in placebotreated patients was 79.3% while in ivacaftortreated patients this value was 76.4%. The mean overall postbaseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week</span><span lang="EN-GB"> 8 in percent predicted FEV<sub>1</sub> (primary efficacy endpoint) was 7.5% in the ivacaftor period and 3.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) (P &lt; 0.0001).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQR through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV<sub>1</sub> at week 8) is shown in Table 7. Based on clinical (percent predicted FEV<sub>1</sub>) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the <i>G970R</i> mutation could not be established.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after: avoid"><b><span lang="EN-GB">Table 7: Effect of ivacaftor for efficacy variables in the overall population and for specific <i>CFTR</i> mutations</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:98.84%;margin-left:5.35pt;border-collapse:collapse;border:none" width="98%"> <tr> <td colspan="2" style="width:32.6%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Absolute change in percent   predicted FEV<sub>1</sub></span></b></p> </td> <td colspan="2" style="width:33.66%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">BMI</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">(kg/m<sup>2</sup>)</span></b></p> </td> <td style="width:33.66%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">CFQ-R respiratory domain score   (points)</span></b></p> </td> </tr> <tr> <td colspan="2" style="width:32.6%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Through week</span></b><b><span lang="EN-GB">8</span></b></p> </td> <td colspan="2" style="width:33.66%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">At week</span></b><b><span lang="EN-GB">8</span></b></p> </td> <td style="width:33.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Through week</span></b><b><span lang="EN-GB">8</span></b></p> </td> </tr> <tr> <td colspan="5" style="width:99.92%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="99%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid;   text-autospace:none"><span lang="EN-GB">All patients (N = 39)</span></p> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid;   text-autospace:none"><span lang="EN-GB">Results shown as mean (95% CI) change   from baseline ivacaftor vs placebotreated patients:</span></p> </td> </tr> <tr> <td colspan="2" style="width:32.6%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">10.7 (7.3, 14.1)</span></p> </td> <td colspan="2" style="width:33.66%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.66 (0.34, 0.99)</span></p> </td> <td style="width:33.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">9.6 (4.5, 14.7)</span></p> </td> </tr> <tr style="height:13.4pt"> <td colspan="5" style="width:99.92%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="99%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid;   text-autospace:none"><b><span lang="EN-GB">Patients grouped under mutation   types (n)</span></b></p> <p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Results shown as mean (minimum, maximum) change from baseline for   ivacaftortreated patients at week 8<sup>*</sup>:</span></p> </td> </tr> <tr style="height:13.4pt"> <td rowspan="2" style="width:16.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="16%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">Mutation (n)</span></b></p> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid;   text-autospace:none"></p> </td> <td colspan="2" style="width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="41%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">Absolute   change in sweat chloride (mmol/L)</span></b></p> </td> <td colspan="2" style="width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="41%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">Absolute   change in percent predicted FEV<sub>1 </sub>(percentage points)</span></b></p> </td> </tr> <tr style="height:13.4pt"> <td colspan="2" style="width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="41%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">At week</span></b><span lang="EN-GB"> <b>8</b></span></p> </td> <td colspan="2" style="width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="41%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">At week</span></b><span lang="EN-GB"> <b>8</b></span></p> </td> </tr> <tr style="height:18.4pt"> <td style="width:16.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt" valign="top" width="16%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><i><span lang="PT">G1244E</span></i><span lang="PT"> (5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><i><span lang="PT">G1349D</span></i><span lang="PT"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><i><span lang="PT">G178R</span></i><span lang="PT"> (5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><i><span lang="PT">G551S</span></i><span lang="PT"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><i><span lang="PT">G970R<sup>#</sup></span></i><sup></sup><span lang="PT">(4)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><i><span lang="EN-GB">S1251N </span></i><span lang="EN-GB">(8)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><i><span lang="EN-GB">S1255P</span></i><span lang="EN-GB"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><i><span lang="EN-GB">S549N</span></i><span lang="EN-GB">   (6)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><i><span lang="EN-GB">S549R</span></i><span lang="EN-GB"> (4)</span></p> </td> <td colspan="2" style="width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.4pt" valign="top" width="41%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span style='font-family:"MS Mincho"'></span><span lang="EN-GB">55 (-75, -34)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">-80 (-82, -79)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">-53 (-65, -35)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">-68<sup><span style="position:relative;   top:-3.0pt"></span></sup></span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">-6 (-16, -2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">-54 (-84, -7)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">-78 (-82, -74)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">-74 (-93, -53)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">-61<sup><span style="position:relative;   top:-3.0pt"></span></sup> (-71, -54)</span></p> </td> <td colspan="2" style="width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.4pt" valign="top" width="41%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">8 (-1, 18)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">20 (3, 36)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">8 (-1, 18)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">3<sup><span style="position:relative;   top:-3.0pt"></span></sup></span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">3 (-1, 5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">9 (-20, 21)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">3 (-1, 8)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">11 (-2, 20)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">5 (-3, 13)</span></p> </td> </tr> <tr height="0"> <td style="border:none" width="112"></td> <td style="border:none" width="116"></td> <td style="border:none" width="177"></td> <td style="border:none" width="58"></td> <td style="border:none" width="235"></td> </tr> </table><p class="MsoNormal" style="margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">*</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Statistical testing was not performed due to small numbers for individual mutations.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt"></span></sup><span lang="EN-GB" style="font-size:9.0pt">     Reflects results from the one patient with the <i>G551S</i> mutation with data at the 8week time point.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt"></span></sup><span lang="EN-GB" style="font-size:9.0pt">    n = 3 for the analysis of absolute change in sweat chloride.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">#</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Causes a splicing defect resulting in little-to-no CFTR protein at the cell surface</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV<sub>1</sub> following 16 weeks (patients randomised to the ivacaftor/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the followup visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1 </sub>from<sub> </sub>part 2 week 16 was 5.9% (9.4%). For patients randomised to the placebo/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV<sub>1</sub> after the additional 16 weeks of treatment with ivacaftor. At the follow up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1</sub> from part 2 week 16 was 7.4% (5.5%).</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Study 3: study in patients with CF with the F508del mutation in the CFTR gene</span></u></i></p><p class="labeltext" style="page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Study 3 (part A) was a 16week, 4:1 randomised, doubleblind, placebocontrolled, parallelgroup phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the <i>F508del</i> mutation in the <i>CFTR</i> gene and who had FEV<sub>1</sub>  40% predicted.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The mean absolute change from baseline through week 16 in percent predicted FEV<sub>1</sub> (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and 0.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI 0.6, 4.1); this difference was not statistically significant (P = 0.15).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB">Study 4: openlabel extension study</span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">In study 4 patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo/ivacaftor group and at least 144 weeks for patients in the ivacaftor/ivacaftor group.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">One hundred and fortyfour (144) patients from study 1 were rolled over in study 4, 67 in the placebo/ivacaftor group and 77 in the ivacaftor/ivacaftor group. Fortyeight (48) patients from study 2 were rolled over in study 4, 22 in the placebo/ivacaftor group and 26 in the ivacaftor/ivacaftor group.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Table 8 shows the results of the mean (SD) absolute change in percent predicted FEV<sub>1</sub> for both groups of patients. For patients in the placebo/ivacaftor group baseline percent predicted FEV<sub>1</sub> is that of study 4 while for patients in the ivacaftor/ivacaftor group the baseline value is that of studies 1 and 2.</span></p><p class="labeltext"></p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span style="font-size:11.0pt">Table 8: Effect of ivacaftor on percent predicted FEV</span></b><sub>1</sub><b><span style="font-size:11.0pt"> in study 4</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:.05in;border-collapse:collapse;border:none"> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Original study and treatment group</span></b></p> </td> <td style="width:31.62%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Duration of ivacaftor treatment (weeks)</span></b></p> </td> <td colspan="2" style="width:46.44%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="46%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Absolute change from baseline in   percent predicted FEV<sub>1 </sub>(percentage points)</span></b></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal"></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">N</span></b></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Mean (SD)</span></b></p> </td> </tr> <tr> <td colspan="4" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Study 1</span></b></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="margin-left:28.35pt;line-height:normal"><b><span lang="EN-GB">Ivacaftor</span></b></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">48<sup>*</sup></span></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">77</span></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">9.4 (8.3)</span></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal"></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">144</span></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">72</span></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">9.4 (10.8)</span></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="margin-left:28.35pt;line-height:normal"><b><span lang="EN-GB">Placebo</span></b></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0<sup>*</sup></span></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">67</span></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">1.2 (7.8)<sup><span style="position:relative;top:-3.0pt"></span></sup></span></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal"></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">96</span></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">55</span></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">9.5 (11.2)</span></p> </td> </tr> <tr> <td colspan="4" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Study 2</span></b></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="margin-left:28.35pt;line-height:normal"><b><span lang="EN-GB">Ivacaftor</span></b></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">48<sup>*</sup></span></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">26</span></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">10.2 (15.7)</span></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal"></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">144</span></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">25</span></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">10.3 (12.4)</span></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="margin-left:28.35pt;line-height:normal"><b><span lang="EN-GB">Placebo</span></b></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0<sup>*</sup></span></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">22</span></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.6 (10.1)<sup><span style="position:relative;top:-3.0pt"></span></sup></span></p> </td> </tr> <tr> <td style="width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal"></p> </td> <td style="width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">96</span></p> </td> <td style="width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">21</span></p> </td> <td style="width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">10.5 (11.5)</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">*</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Treatment occurred during blinded, controlled, 48week phase 3 study.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt; position:relative;top:-3.0pt"></span></sup><span lang="EN-GB" style="font-size:9.0pt">Change from prior study baseline after 48 weeks of placebo treatment.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">When the mean (SD) absolute change in percent predicted FEV<sub>1</sub> is compared from study 4 baseline for patients in the ivacaftor/ivacaftor group (n = 72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV<sub>1</sub> was 0.0% (9.05), while for patients in the ivacaftor/ivacaftor group (n = 25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor/ivacaftor group maintained the improvement seen at week</span><span lang="EN-GB" style="font-size:11.0pt">48 of the initial study (day</span><span lang="EN-GB" style="font-size:11.0pt">0 through week 48) in percent predicted FEV<sub>1</sub> through week 144. There were no additional improvements in study 4 (week 48 through week 144).</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">For patients in the placebo/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events/year across day</span><span lang="EN-GB" style="font-size:11.0pt">1 to week</span><span lang="EN-GB" style="font-size:11.0pt">48, and 0.67 events/year across weeks</span><span lang="EN-GB" style="font-size:11.0pt">48 to 96). For patients in the ivacaftor/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events/year across day 1 to week 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events/year across day</span><span lang="EN-GB" style="font-size:11.0pt">1 to week</span><span lang="EN-GB" style="font-size:11.0pt">48 and 0.77 events/year across weeks 48 to 96.</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">For patients who rolled over from study 2 the number of events was, overall, low.</span></p><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><u>Study 6: study in patients with CF with an R117H mutation in the CFTR gene</u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid">Study 6 evaluated 69 patients who were 6 years of age or older; 53 (76.8%) patients had the <i>F508del</i> mutation in the second allele. The confirmed <i>R117H </i>polyT variant was <i>5T </i>in 38 patientsand <i>7T </i>in 16 patients. At baseline, mean predicted FEV<sub>1</sub> was 73% (range: 32.5% to 105.5%) and mean age was 31 years (range: 6 to 68 years). The mean absolute change from baseline through week 24 in percent predicted FEV<sub>1</sub> (primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 2.1 percentage points (95% CI 1.1, 5.4).</p><p class="MsoNormal" style="line-height:normal"> </p><p class="MsoNormal" style="line-height:normal">A preplanned subgroup analysis was conducted in patients 18 years and older (26 patients on placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in percent predicted FEV<sub>1</sub> through week 24 of 4.5 percentage points in the ivacaftor group versus 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 5.0 percentage points (95% CI 1.1, 8.8).</p><p class="MsoNormal" style="line-height:normal"> </p><p class="MsoNormal" style="line-height:normal">In a subgroup analysis in patients with a confirmed <i>R117H5T </i>genetic variant, the difference in the mean absolute change from baseline through week24 in percent predicted FEV<sub>1</sub> between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a confirmed <i>R117H7T </i>genetic variant, the treatment difference between ivacaftor and placebo was 0.2% (95% CI 8.1, 8.5).</p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><a name="_Hlk37921752"><span lang="EN-GB">For secondary efficacy variables, no treatment differences were observed for ivacaftor versus placebo in absolute change from baseline in BMI at week 24 or time to first pulmonary exacerbation. Treatment differences were observed in absolute change in CFQR respiratory domain score through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from baseline in sweat chloride (see Pharmacodynamic effects).</span></a></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Ivacaftor in a combination regimen with tezacaftor/ivacaftor or with ivacaftor/tezacaftor/elexacaftor</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The efficacy and safety of ivacaftor in a combination regimen with tezacaftor/ivacaftor in patients with CF aged 12 years and older was assessed in two clinical studies; a 24 week, randomised, doubleblind, placebocontrolled study with 504 patients who were homozygous for the <i>F508del </i>mutation; and a randomised, doubleblind, placebocontrolled and ivacaftor controlled, 2 period, 3 treatment, 8week crossover study with 244 patients who were heterozygous for the <i>F508del</i> mutation and a second mutation associated with residual <i>CFTR </i>activity. The long-term safety and efficacy of the combination regimen was also assessed in both patient populations in a 96-week open-label, rollover, long-term extension study. Refer to the Summary of Product Characteristics of tezacaftor/ivacaftor for additional data.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The efficacy and safety of ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor in patients aged 12 years and older was demonstrated in two, phase 3 studies, randomised, double blind, placebo-controlled (heterozygous <i>F508del</i> patients, n=403) and active-controlled (homozygous <i>F508del</i> patients, n=107) of 24 and 4 weeks of duration, respectively. Heterozygous <i>F508del</i> patients had a minimal function mutation on the second allele defined as one that either leads to </span><span lang="EN-GB">no CFTR protein being produced (e.g. Class I) or a CFTR protein that does not function to transport chloride and is unlikely to respond to other CFTR modulators (tezacaftor, ivacaftor or the combination of both). Homozygous <i>F508del</i> patients received tezacaftor/ivacaftor and ivacaftor regimen during a 4-week open-label run-in period and were then randomised and dosed to receive ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor during a 4-week double-blind treatment period. Patients from both studies were eligible to enter an openlabel, rollover, 96-week study. Refer to the Summary of Product Characteristics of ivacaftor/tezacaftor/elexacaftor for additional data.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis (see section 4.2 for information on paediatric use).</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean ( SD) for AUC and C<sub>max</sub> were 10600 (5260) ng*hr/mL and 768 (233) ng/mL, respectively. After every 12hour dosing, steadystate plasma concentrations of ivacaftor were reached by days</span><span lang="EN-GB">3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="labeltextheading"><u><span lang="EN-GB" style="font-size:11.0pt; font-style:normal">Absorption</span></u></p><p class="labeltextheading"><u><span lang="EN-GB" style="font-size:11.0pt; font-style:normal"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food, the exposure of ivacaftor increased approximately 2.5 to 4fold. When co-administered with tezacaftor and elexacaftor, the increase in AUC was similar (approximately 3fold and 2.5-to 4-fold respectively). Therefore, ivacaftor, administered as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor, should be administered with fatcontaining food. The median (range) t<sub>max</sub> is approximately 4.0 (3.0; 6.0) hours in the fed state.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Ivacaftor granules (2 x 75 mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC<sub>0</sub> and 0.918 (0.750, 1.12) for C<sub>max</sub>. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB">Distribution</span></u></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells. After oral administration of ivacaftor150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean ( SD) apparent volume of distribution was 353 L (122) .</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Biotransformation</span></u></p><p class="labeltext" style="page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor is extensively metabolised in humans. <i>In vitro</i> and <i>in vivo</i> data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately onesixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than onefiftieth the potency of ivacaftor and is not considered pharmacologically active.</span></p><p class="labeltext"></p><p class="labeltext"><span style="font-size:11.0pt">The effect of the CYP3A4*22 heterozygous genotype on tezacaftor, ivacaftor and elexacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose-adjustment of tezacaftor, ivacaftor or elexacaftor is considered necessary. The effect in CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Elimination</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal halflife was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean ( SD) CL/F for a single 150 mg dose was 17.3 (8.4) L/hr in healthy subjects.</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Linearity/nonlinearity</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 25 mg to 250 mg.</span></p><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Special populations</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltextheading"><a name="_Hlk45278559"><span lang="EN-GB" style="font-size:11.0pt">Hepatic impairment</span></a></p><p class="labeltextheading"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (ChildPugh Class B, score 7 to 9) had similar ivacaftor C<sub>max</sub> (mean [ SD] of 735 [331] ng/mL) but an approximately twofold increase in ivacaftor AUC<sub>0-</sub> (mean [ SD] of 16800 [6140] ng*hr/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steadystate exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steadystate C<sub>min</sub> values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. </span></p><p class="labeltext"></p><p class="MsoNormal">In subjects with moderately impaired hepatic function (Child Pugh Class B, score 7 to 9), ivacaftor AUC increased approximately by 50% following multiple doses for 10 days of either tezacaftor and ivacaftor or of ivacaftor, tezacaftor and elexacaftor. </p><p class="MsoNormal"> </p><p class="labeltext"><span style="font-size:11.0pt">The impact of severe hepatic impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of ivacaftor as monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor has not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment. </span></p><p class="labeltext"></p><p class="labeltext"><span style="font-size:11.0pt">For guidance on appropriate use and dose modification see Table 3 in section 4.2.</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Renal impairment</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment, either as monotherapy or in a combination regimen with tezacaftor/ivacaftor </span>or with <span lang="EN-GB" style="font-size:11.0pt">ivacaftor/tezacaftor/elexacaftor. In a human pharmacokinetic study with ivacaftor monotherapy, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). </span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">No dose adjustments are recommended for mild and moderate renal impairment. Caution is recommended when administering ivacaftor, either as monotherapy or in a combination with tezacaftor/ivacaftor or with ivacaftor/tezacaftor/elexacaftor, to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or endstage renal disease (see sections 4.2 and 4.4).</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Race</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Race had no clinically meaningful effect on the PK of ivacaftor in white (n = 379) and non-white (n = 29) patients based on a population PK analysis.</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Gender</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">The pharmacokinetic parameters of ivacaftor, either as monotherapy or in combination with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor, are similar in males and females.</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Elderly</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Clinical studies of ivacaftor monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.</span></p><p class="labeltext"></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"><span lang="EN-GB">The pharmacokinetic parameters of ivacaftor in combination with tezacaftor in the elderly patients (6572 years) are comparable to those in younger adults. No patients aged 65 years and older were included in the clinical studies of ivacaftor/tezacaftor/elexacaftor and therefore it cannot be </span>determined whether pharmacokinetic parameters are similar or not to those in younger adults<span lang="EN-GB">.</span></p><p class="labeltext"></p><p class="labeltextheading"><u><span lang="EN-GB" style="font-size:11.0pt; font-style:normal">Paediatric population</span></u></p><p class="labeltextheading"><u><span lang="EN-GB" style="font-size:11.0pt; font-style:normal"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid">Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 9.</p><p class="MsoNormal" style="line-height:normal"> </p><p class="MsoNormal" style="margin-bottom:6.0pt;line-height:normal;page-break-after: avoid"><b>Table 9: Mean (SD) ivacaftor exposure by age group</b></p><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:101.48%;margin-left:5.35pt;border-collapse:collapse" width="101%"> <tr style="height:23.9pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;padding:   0in 5.4pt 0in 5.4pt;height:23.9pt" width="55%"> <p align="center" class="MsoNormal" style="margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid"><b>Age group</b></p> </td> <td style="width:14.96%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" width="14%"> <p align="center" class="MsoNormal" style="margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid"><b>Dose</b></p> </td> <td style="width:13.1%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" width="13%"> <p align="center" class="MsoNormal" style="margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid"><b>C<sub>min, ss</sub> (ng/mL)</b></p> </td> <td style="width:16.2%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" width="16%"> <p align="center" class="MsoNormal" style="margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid"><b><span lang="PT">AUC</span><sub><span lang="EN-GB"></span></sub></b><b><sub><span lang="PT">, ss</span></sub></b><b><span lang="PT"> (ng*h/mL)</span></b></p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" width="55%"> <p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid">6 months   to less than 12 months (5 kg to &lt; 7 kg)<span class="MsoCommentReference"></span><sup>*</sup></p> </td> <td style="width:14.96%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" width="14%"> <p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid">25 mg   q12h</p> </td> <td style="width:13.1%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" width="13%"> <p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><span lang="EN-GB">336</span></p> </td> <td style="width:16.2%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" width="16%"> <p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><span lang="EN-GB">5410</span></p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" width="55%"> <p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid">6 months   to less than 12 months (7 kg to &lt; 14 kg)</p> </td> <td style="width:14.96%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" width="14%"> <p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid">50 mg   q12h</p> </td> <td style="width:13.1%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" width="13%"> <p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><span lang="EN-GB">508 (252)</span></p> </td> <td style="width:16.2%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" width="16%"> <p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><span lang="EN-GB">9140 (4200)</span></p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="55%"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">12 months to less than 24 months (7 kg to   &lt; 14 kg)</span></p> </td> <td style="width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="14%"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">50 mg q12h</span></p> </td> <td style="width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="13%"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">440 (212)</span></p> </td> <td style="width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="16%"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">9050 (3050)</span></p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="55%"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">12 months to less than 24 months (</span><span style="font-size:11.0pt;font-family:SimSun"></span><span style="font-size:11.0pt"> 14 kg to &lt; 25 kg)</span></p> </td> <td style="width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="14%"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">75 mg q12h</span></p> </td> <td style="width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="13%"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">451 (125)</span></p> </td> <td style="width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="16%"> <p class="labeltext" style="page-break-after:avoid"><span style="font-size:   11.0pt">9600 (1800)</span></p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="55%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">2   to 5year-olds (&lt; 14 kg)</p> </td> <td style="width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="14%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">50 mg q12h</p> </td> <td style="width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">577   (317)</p> </td> <td style="width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="16%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">10500   (4260)</p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="55%"> <p class="MsoNormal" style="line-height:normal">2 to 5year-olds ( 14 kg   to &lt; 25 kg)</p> </td> <td style="width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="14%"> <p class="MsoNormal" style="line-height:normal">75 mg q12h</p> </td> <td style="width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal">629 (296)</p> </td> <td style="width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="16%"> <p class="MsoNormal" style="line-height:normal">11300 (3820)</p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="55%"> <p class="MsoNormal" style="line-height:normal">6 to 11year-olds <sup></sup>   ( 14 kg to &lt; 25 kg)</p> </td> <td style="width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="14%"> <p class="MsoNormal" style="line-height:normal">75 mg q12h</p> </td> <td style="width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal">641 (329)</p> </td> <td style="width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="16%"> <p class="MsoNormal" style="line-height:normal">10760 (4470)</p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="55%"> <p class="MsoNormal" style="line-height:normal">6 to 11year-olds <sup></sup>   ( 25 kg)</p> </td> <td style="width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="14%"> <p class="MsoNormal" style="line-height:normal">150 mg q12h</p> </td> <td style="width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal">958 (546)</p> </td> <td style="width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="16%"> <p class="MsoNormal" style="line-height:normal">15300 (7340)</p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="55%"> <p class="MsoNormal" style="line-height:normal">12 to 17year-olds   </p> </td> <td style="width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="14%"> <p class="MsoNormal" style="line-height:normal">150 mg q12h</p> </td> <td style="width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal">564 (242)</p> </td> <td style="width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="16%"> <p class="MsoNormal" style="line-height:normal">9240 (3420)</p> </td> </tr> <tr style="height:19.0pt"> <td style="width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="55%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">Adults   ( 18 years old) </p> </td> <td style="width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="14%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">150 mg q12h</p> </td> <td style="width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">701   (317)</p> </td> <td style="width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt" valign="top" width="16%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">10700   (4100)</p> </td> </tr> </table><p class="MsoNormal" style="margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span style="font-size:9.0pt">*</span></sup><span style="font-size:9.0pt">     Values based on data from a single patient; standard deviation not reported.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt; position:relative;top:-3.0pt"></span></sup><span style="font-size:9.0pt">     Exposures in 6 to 11yearolds are predictions based on simulations from the population PK model using data obtained for this age group.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The pharmacokinetic parameters of ivacaftor in combination with tezacaftor and with tezacaftor/elexacaftor in adolescent patients (12 to 17-year-olds) are similar to that of adult patients (see Table 10).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-bottom:6.0pt;line-height:normal;page-break-after: avoid"><b>Table 10: Mean (SD) of ivacaftor exposure when used in combination with tezacaftor and in combination with tezacaftor/elexacaftor, by age group</b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:467.55pt;border-collapse:collapse;border:none" width="623"> <tr style="height:26.55pt"> <td style="width:40.88%;border:solid windowtext 1.0pt;padding:   0in 0in 0in 0in;height:26.55pt" width="40%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Age group</span></b></p> </td> <td style="width:27.28%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 0in 0in 0in;height:26.55pt" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Dose</span></b></p> </td> <td style="width:31.84%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 0in 0in 0in;height:26.55pt" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Ivacaftor Mean (SD)</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">AUC<sub>0-12h</sub>,ss (ng*h/mL)</span></b></p> </td> </tr> <tr style="height:13.0pt"> <td style="width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt" width="40%"> <p class="MsoNormal" style="margin-left:4.5pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Adolescent patients (12 to &lt;18 years) </span></p> <p class="MsoNormal" style="margin-left:4.5pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">n = 97</span></p> </td> <td rowspan="2" style="width:27.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="PT">tezacaftor 100 mg qd/ <br/>   ivacaftor 150 mg q12h</span></p> </td> <td style="width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">11400 (5500)</span></p> </td> </tr> <tr style="height:13.0pt"> <td style="width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt" width="40%"> <p class="MsoNormal" style="margin-left:4.5pt;line-height:normal;page-break-after:   avoid">Adult patients ( 18 years)</p> <p class="MsoNormal" style="margin-left:4.5pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">n = 389</span></p> </td> <td style="width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">11400 (4140)</span></p> </td> </tr> <tr style="height:13.0pt"> <td style="width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt" width="40%"> <p class="MsoNormal" style="margin-left:4.5pt;line-height:normal;page-break-after:   avoid">Adolescent patients (12 to &lt;18 years)</p> <p class="MsoNormal" style="margin-left:4.5pt;line-height:normal;page-break-after:   avoid">n = 69</p> </td> <td rowspan="2" style="width:27.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid">elexacaftor 200 mg qd/<br/>   tezacaftor 100 mg qd/<br/>   ivacaftor 150 mg q12h</p> </td> <td style="width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid">10600 (3350)</p> </td> </tr> <tr style="height:13.0pt"> <td style="width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt" width="40%"> <p class="MsoNormal" style="margin-left:4.5pt;line-height:normal;page-break-after:   avoid">Adult patients (18 years)</p> <p class="MsoNormal" style="margin-left:4.5pt;line-height:normal;page-break-after:   avoid">n = 186</p> </td> <td style="width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid">12100 (4170)</p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Pregnancy and fertility</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The NoObservedAdverseEffectLevel (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Peri and postnatal development</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level of approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Juvenile animal studies</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7week old rats, nor in 3.5 to 5month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Tablet core</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Cellulose, microcrystalline</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Lactose monohydrate</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Hypromellose acetate succinate</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Croscarmellose sodium</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Sodium laurilsulfate (E487)</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Silica, colloidal anhydrous</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Magnesium stearate</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="IT">Tablet film coat</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="IT"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Polyvinyl alcohol</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Titanium dioxide (E171)</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="PT">Macrogol (PEG 3350)</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="PT">Talc</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="PT">Indigo carmine aluminium lake (E132)</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid">Carnauba wax</p><p class="MsoNormal" style="line-height:normal"> </p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u>Printing ink</u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid">Shellac</p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid">Iron oxide black (E172)</p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Propylene glycol (E1520)</span></p><p class="MsoNormal" style="line-height:normal"><span lang="IT">Ammonia solution, concentrated</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not applicable.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">4 years.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">This medicinal product does not require any special storage conditions.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The film-coated tablets are packed in a thermoform (PolyChloroTriFluoroEthylene [PCTFE]/foil) blister or a High-Density PolyEthylene (HDPE) bottle with </span><span lang="EN-GB">a polypropylene child-resistant closure, foil-lined induction seal and molecular sieve</span><span lang="EN-GB"> desiccant.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The following pack sizes are available:</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt; font-family:Symbol">-</span><span lang="EN-GB">Blister card pack containing 28 filmcoated tablets</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt; font-family:Symbol">-</span><span lang="EN-GB">Blister pack containing 56 filmcoated tablets</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;line-height: normal"><span lang="EN-GB" style="font-size:8.0pt;font-family:Symbol">-</span><span lang="EN-GB">Bottle containing 56 filmcoated tablets</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal">Not all pack sizes may be marketed</p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6    Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Vertex Pharmaceuticals (Ireland) Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">28-32 Pembroke Street Upper</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dublin 2, D02 EK84</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ireland</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">EU/1/12/782/001</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">EU/1/12/782/002</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">EU/1/12/782/005</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Date of first authorisation: 23 July 2012</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Date of latest renewal: 28 April 2017</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency <u>http://www.ema.europa.eu</u>.</span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Kalydeco 25 mg granules in sachet</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Kalydeco 50 mg granules in sachet</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Kalydeco 75 mg granules in sachet</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Kalydeco 25 mg granules in sachet</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Each sachet contains 25 mg of ivacaftor.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Excipient with known effect</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Each sachet contains 36.6 mg of lactose monohydrate.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Kalydeco 50 mg granules in sachet</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Each sachet contains 50 mg of ivacaftor.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Excipient with known effect</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Each sachet contains 73.2 mg of lactose monohydrate.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Kalydeco 75 mg granules in sachet</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Each sachet contains 75 mg of ivacaftor.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Excipient with known effect</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Each sachet contains 109.8 mg of lactose monohydrate.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none"><span lang="EN-GB">Granules in sachet</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">White to offwhite granules approximately 2 mm in diameter.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an <i>R117H CFTR</i> mutation or one of the following gating (class III) mutations in the <i>CFTR</i> gene: <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N </i>or<i> S549R</i> (see sections 4.4 and 5.1).</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. </span>If the patient's genotype is unknown, an <span lang="EN-GB">accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in at least one allele of the <i>CFTR</i> gene (see section 4.1). The phase of the poly-T variant identified with the <i>R117H </i>mutation should be determined in accordance with local clinical recommendation.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Infants aged at least 4 months, toddlers, children, adolescents and adults should be dosed according to Table 1.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="margin-bottom:6.0pt;line-height:normal;page-break-after: avoid"><b><span lang="EN-GB">Table 1: Dosing recommendations for patients aged 4 months and older</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.0%;border-collapse:collapse;border:none" width="99%"> <tr style="height:10.85pt"> <td style="width:21.68%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Age</span></b></p> </td> <td style="width:21.68%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Weight</span></b></p> </td> <td style="width:36.18%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Dose</span></b></p> </td> <td style="width:20.46%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Total daily dose</span></b></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">4 months to less than 6 months</span></p> </td> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span style="font-family:SimSun"></span><span lang="EN-GB">5 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">25 mg granules taken orally every 12 hours with fat-containing   food</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">50 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td rowspan="4" style="width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">6 months and older</span></p> </td> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span style="font-family:SimSun"></span><span lang="EN-GB">5 kg to   &lt; 7 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">25 mg granules taken orally every 12 hours with fatcontaining   food</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">50 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span style="font-family:SimSun"></span><span lang="EN-GB"> 7 kg to &lt; 14 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">50 mg granules taken orally every 12 hours with fatcontaining   food</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">100 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span style="font-family:SimSun"></span><span lang="EN-GB"> 14 kg to   &lt; 25 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">75 mg granules taken orally every 12 hours with fatcontaining   food</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">150 mg</span></p> </td> </tr> <tr style="height:15.7pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt" valign="top" width="21%"> <p class="MsoNormal" style="line-height:normal"><span style="font-family:SimSun"></span><span lang="EN-GB"> 25 kg</span></p> </td> <td colspan="2" style="width:56.64%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt" valign="top" width="56%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">See Kalydeco   tablets SmPC for further details.</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal"><span class="s10"></span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span class="s10"><i><span lang="EN-GB">Missed dose</span></i></span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span class="s10"></span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span class="s10"><span lang="EN-GB">If 6 hours or less have passed since the missed morning or evening dose, the patient should take it as soon as possible and continue on the original schedule. If more than 6 hours have passed since the time the dose is usually taken, the patient should be told to wait until the next scheduled dose.</span></span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><i><span style="font-size: 11.0pt">Concomitant use of CYP3A inhibitors</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">When co-administered with strong inhibitors of CYP3A in patients aged 6 months and older, the </span><span lang="EN-GB" style="font-size:11.0pt">ivacaftor dose should be reduced to one sachet (ivacaftor 25 mg for patients 5 kg to &lt; 7 kg; ivacaftor 50 mg for patients 7 kg to &lt; 14 kg; ivacaftor 75 mg for patients 14 kg to &lt; 25 kg) twice a week </span><span style="font-size:11.0pt">(see sections 4.4 and 4.5).</span></p><p class="labeltext"></p><p class="labeltext"><span style="font-size:11.0pt">When co-administered with moderate inhibitors of CYP3A in patients aged 6 months and older,</span><span lang="EN-GB" style="font-size:11.0pt"> the ivacaftor dose is as above recommended but administered once daily </span><span style="font-size:11.0pt">(see sections 4.4 and 4.5).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Due to the variability in maturation of the cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended when co-administered with moderate or strong inhibitors of CYP3A in patients aged 4 months to less than 6 months, unless the benefits outweigh the risks. In such cases, the recommended dose is one packet of 25 mg granules twice weekly or less frequently (see sections 4.4 and 4.5). Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2)</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Special populations</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or endstage renal disease (see sections 4.4 and 5.2).</span></p><p class="labeltextheading"></p><p class="labeltextheading"><span style="font-size:11.0pt">Hepatic impairment</span></p><p class="labeltextheading"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">No dose adjustment is necessary for patients aged 6 months and older with mild hepatic impairment (ChildPugh Class A). For patients aged 6 months and older with moderate hepatic impairment (ChildPugh Class B), a </span><span style="font-size:11.0pt">reduced dose of one sachet (ivacaftor 25 mg for patients 5 kg to &lt; 7 kg; ivacaftor 50 mg for patients 7 kg to &lt; 14 kg; ivacaftor 75 mg for patients 14 kg to &lt; 25 kg) once daily is recommended. There is no experience of the use of ivacaftor in patients aged 6 months and older with severe hepatic impairment (Child-Pugh Class C); therefore, its use is not recommended unless the benefits outweigh the risks. In such cases, the starting dose should be as above recommended, administered </span><span lang="EN-GB" style="font-size:11.0pt">every other day</span><span style="font-size:11.0pt">. Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).</span></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext"><span style="font-size:11.0pt">Due to variability in maturation of cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended in patients aged 4 months to less than 6 months with hepatic impairment, unless the benefits outweigh the risks. In such cases, the recommended dose is one sachet (ivacaftor 25 mg) once daily or less frequently. Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).</span></p><p class="labeltext" style="page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b></b></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">The safety and efficacy of ivacaftor in children aged less than 4 months have not been established. No data are available.</span></p><p class="labeltext"></p><p class="labeltext"><span style="font-size:11.0pt">Limited data are available in patients less than 6 years of age with an <i>R117H</i> mutation in the <i>CFTR</i> gene. Available data in patients aged 6 years and older are described in sections 4.8, 5.1 and 5.2.</span></p><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Method of administration </span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">For oral use.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Each sachet is for single use only.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Each sachet of granules should be mixed with 5 mL of ageappropriate soft food or liquid and</span><span lang="EN-GB"> completely and immediately consumed. </span>Food or liquid should be at room temperature or below. <span lang="EN-GB">If not immediately consumed, the mixture has been shown to be stable for one hour and therefore should be ingested during this period. A fatcontaining meal or snack should be consumed just before or just after dosing.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Food or drink containing grapefruit should be avoided during treatment (see section 4.5).</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3       Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4       Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Only patients with CF who had a <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N</i> or <i>S549R</i> gating (class III) or <i>G970R</i> mutation in at least one allele of the <i>CFTR</i> gene were included in studies 1, 2, 5 and 7 (see section</span><span lang="EN-GB"> 5.1).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Less evidence of a positive effect of ivacaftor has been shown for patients with an <i>R117H-7T</i> mutation associated with less severe disease in study 6 (see section 5.1).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In study 5, four patients with the <i>G970R</i> mutation were included. In three of four patients the change in the sweat chloride test was &lt; 5</span><span lang="EN-GB"> mmol/L and this group did not demonstrate a clinically relevant improvement in FEV<sub>1</sub> after 8 weeks of treatment. Clinical efficacy in patients with the <i>G970R</i> mutation of the <i>CFTR</i> gene could not be established (see section 5.1).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Efficacy results from a phase 2 study in patients with CF who are homozygous for the <i>F508del </i>mutation in the <i>CFTR</i> gene showed no statistically significant difference in FEV<sub>1</sub> over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1). Therefore, use of ivacaftor as monotherapy in these patients is not recommended.</span></p><p class="labeltextheading"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Effect on liver function tests</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in subjects with CF. Transaminase elevations have been observed in some patients treated with ivacaftor monotherapy. Therefore, liver function tests are recommended for all patients prior to initiating ivacaftor, every 3</span><span style="font-size:11.0pt">months during the first year of treatment and annually thereafter. </span><span style="font-size:11.0pt">For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. </span><span style="font-size:11.0pt">In the event of significant elevations of transaminases (e.g., patients with ALT or AST &gt; 5 x the upper limit of normal (ULN), or ALT or AST &gt; 3 x ULN with bilirubin &gt; 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see section 4.8).</span></p><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Hepatic impairment</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Use of ivacaftor is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks (see sections 4.2 and 5.2). No safety data are available in infants aged 4 to less than 12 months of age with moderate or severe hepatic impairment treated with ivacaftor.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Renal impairment</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">Caution is recommended while using ivacaftor in patients with severe renal impairment or endstage renal disease (see sections 4.2 and 5.2).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Patients after organ transplantation</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ivacaftor has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with ciclosporin or tacrolimus.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt">Interactions with medicinal products</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><span style="font-size: 11.0pt">CYP3A inducers</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">Exposure to ivacaftor is significantly decreased by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, </span><span lang="EN-GB" style="font-size:11.0pt">co-administration </span><span style="font-size:11.0pt">of ivacaftor </span><span lang="EN-GB" style="font-size: 11.0pt">with strong CYP3A inducers is not recommended</span><span style="font-size:11.0pt"> (see section 4.5).</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><i><span style="font-size: 11.0pt">CYP3A inhibitors </span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">Exposure to ivacaftor is increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor must be adjusted when used concomitantly with strong or moderate CYP3A inhibitors (see sections 4.2 and 4.5). No safety data are available in infants aged 4 to less than 12 months of age who are treated with ivacaftor and moderate or strong CYP3A inhibitors (see sections 4.2 and 4.5).</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population </span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Cases of noncongenital lens opacities/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and followup ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Lactose content</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicine.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Sodium content</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodiumfree.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and Pgp and a potential inhibitor of CYP2C9. </span><i><span lang="EN-GB">In vitro</span></i><span lang="EN-GB"> studies showed that ivacaftor is not a substrate for Pgp. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Medicinal products affecting the pharmacokinetics of ivacaftor</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">CYP3A inducers</span></i></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Coadministration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor. Coadministration of ivacaftor with strong CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. Johns wort (<i>Hypericum perforatum</i>), is not recommended (see section 4.4).</span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="MsoCommentText" style="line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">No dose adjustment is recommended when ivacaftor is used with moderate or weak CYP3A inducers. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="labeltext" style="page-break-after:avoid"><i><span style="font-size: 11.0pt">CYP3A inhibitors</span></i></p><p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor is a sensitive CYP3A substrate. Coadministration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5fold and increased M1 to a lesser extent than ivacaftor. A reduction of the </span><span style="font-size:11.0pt">ivacaftor dose </span><span lang="EN-GB" style="font-size:11.0pt">is recommended for coadministration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see sections 4.2 and 4.4).</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Coadministration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3fold and increased M1 to a lesser extent than ivacaftor. A reduction of the </span><span style="font-size:11.0pt">ivacaftor dose is recommended </span><span lang="EN-GB" style="font-size:11.0pt">for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections 4.2 and 4.4).</span></p><p class="labeltext"></p><p class="labeltext"><span lang="EN-GB" style="font-size:11.0pt">Co-administration of ivacaftor with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with ivacaftor (see section 4.2).</span></p><p class="labeltext"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Potential for ivacaftor to interact with transporters</span></u></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">In vitro</span></i><span lang="EN-GB" style="font-size:11.0pt"> studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP <i>in vitro</i>. Due to its high intrinsic permeability and low likelihood of being excreted intact, coadministration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1IVA, while any potential changes in M6IVA exposures are not expected to be clinically relevant. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Ciprofloxacin</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">Co-administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when ivacaftor is coadministered with ciprofloxacin.</span></p><p class="labeltext"></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt">Medicinal products affected by ivacaftor</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt"></span></u></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and/or Pgp, and/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.</span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">CYP2C9 substrates</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during coadministration of warfarin with ivacaftor. Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.</span></p><p class="MsoCommentText" style="line-height:normal"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Digoxin and other Pgp substrates</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Coadministration with digoxin, a sensitive Pgp substrate, increased digoxin exposure by 1.3fold, consistent with weak inhibition of Pgp by ivacaftor. Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of Pgp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly</span><span style="font-size:11.0pt"> with</span><span lang="EN-GB" style="font-size:11.0pt"> digoxin or other substrates of Pgp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.</span></p><p class="MsoCommentText" style="line-height:normal"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">CYP3A substrates </span></i></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Coadministration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are co-administered with ivacaftor. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Hormonal contraceptives</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoCommentText" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Ivacaftor has been studied with an oestrogen/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive.</span><span lang="EN-GB" style="font-size:11.0pt">Therefore, no dose adjustment of oral contraceptives is necessary.</span></p><p style="margin:0in"></p><p style="margin:0in;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Paediatric population</span></u></p><p style="margin:0in;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p style="margin:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size: 11.0pt">Interaction studies have only been performed in adults.</span></p><p style="margin:0in"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6       Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt">Pregnancy</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women.</span><span lang="EN-GB" style="font-size:11.0pt">Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable avoid the use of ivacaftor during pregnancy.</span></p><p class="labeltext"> </p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Breastfeeding</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">It is unknown whether ivacaftor and/or its metabolites are excreted in human milk. </span><span lang="EN-GB" style="font-size:11.0pt">Available pharmacokinetic data in animals have shown excretion of </span><span style="font-size:11.0pt">ivacaftor into the milk of lactating female rats. </span><span lang="EN-GB" style="font-size:11.0pt">As such, a risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ivacaftor therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</span></p><p class="labeltext"> </p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><u><span lang="EN-GB">Fertility</span></u></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3)</span>.</p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ivacaftor has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore, patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt">Summary of the safety profile</span></u></p><p class="labeltext" style="page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The most common adverse reactions experienced by patients aged 6 years and older are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), dizziness (9.2%), rash (12.8%) and bacteria in sputum (12.8%).</span><span lang="EN-GB">Transaminase elevations occurred in 12.8% of ivacaftortreated patients versus 11.5% of placebo-treated patients.</span></p><p class="labeltext"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).</span></p><p class="labeltext"><u><span style="font-size:11.0pt"></span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt">Tabulated list of adverse reactions</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span style="font-size: 11.0pt"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Table 2 reflects the adverse reactions observed with ivacaftor in clinical trials (placebocontrolled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. The frequency of adverse reactions is defined as follows: very common ( 1/10); common ( 1/100 to &lt; 1/10); uncommon ( 1/1,000 to &lt; 1/100); rare ( 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). </span><span lang="EN-GB">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="margin-bottom:6.0pt;line-height:normal;page-break-after: avoid"><b>Table 2: Adverse reactions in ivacaftortreated patients aged 4 months and older</b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:95.28%;margin-left:5.45pt;border-collapse:collapse;border:none" width="95%"> <thead> <tr style="page-break-inside:avoid;height:12.55pt"> <td style="width:32.52%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:12.55pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">System organ class</span></b></p> </td> <td style="width:33.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"><b>Adverse reactions</b></p> </td> <td style="width:33.72%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="NL-BE">Frequency </span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:6.4pt"> <td rowspan="3" style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Infections and   infestations</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Upper   respiratory tract infection</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nasopharyngitis</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.35pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Rhinitis </span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td rowspan="2" style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nervous system   disorders</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Headache</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Dizziness</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td rowspan="6" style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Ear and   labyrinth disorders</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Ear pain</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Ear discomfort</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Tinnitus</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Tympanic   membrane hyperaemia</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Vestibular   disorder</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Ear congestion</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td rowspan="4" style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Respiratory, thoracic and mediastinal disorders</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Oropharyngeal pain</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Nasal congestion</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Sinus congestion </span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:16.6pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Pharyngeal   erythema</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td rowspan="2" style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Gastrointestinal   disorders</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Abdominal pain</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Diarrhoea</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal"><span lang="DA">Hepatobiliary   disorders</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Transaminase   elevations</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Skin and   subcutaneous tissue disorders</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Rash</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td rowspan="5" style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Reproductive   system and breast disorders</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Breast mass</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">common</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Breast   inflammation</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Gynaecomastia</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nipple   disorder</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Nipple pain</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">uncommon</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:16.6pt"> <td style="width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.6pt" valign="top" width="32%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Investigations</span></p> </td> <td style="width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Bacteria in   sputum</span></p> </td> <td style="width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">very common</span></p> </td> </tr> </table><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Description of selected adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Transaminase elevations</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">During the 48week placebocontrolled studies 1 and 2 in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5 or &gt; 3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftor-treated patients and 1.0%, 1.9% and 8.7% in placebo-treated patients, respectively. Two patients, one on placebo and one on ivacaftor, permanently discontinued treatment for elevated transaminases, each &gt; 8 x ULN. No ivacaftortreated patients experienced a transaminase elevation &gt; 3 x ULN associated with elevated total bilirubin &gt; 1.5 x ULN. In ivacaftor-treated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations &gt; 5 x ULN. In all instances where dosing was interrupted for elevated transaminases and </span><span lang="EN-GB">subsequently resumed, ivacaftor</span><span lang="EN-GB"> dosing was able to be resumed successfully (see section 4.4).</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">During the placebo controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5, or &gt; 3 x ULN were 0.2%, 1.0%, and 3.4% in tezacaftor/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%) on placebo permanently discontinued treatment for elevated transaminases. No patients treated with tezacaftor/ivacaftor experienced a transaminase elevation &gt;3 x ULN associated with elevated total bilirubin &gt;2 x ULN. </span></p><p class="MsoNormal"> </p><p class="MsoNormal"><span lang="EN-GB">During the 24-week, placebo-controlled, phase 3 study of ivacaftor/tezacaftor/elexacaftor, these figures were 1.5%, 2.5%, and 7.9% in ivacaftor/tezacaftor/elexacaftor-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor treated patients and 4.0% in placebo-treated patients.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The safety data of ivacaftor were evaluated in 6 patients between 4 months to less than 6 months of age, 11 patients between 6 months to less than 12 months of age, 19 patients between 12 months to less than 24 months of age, 34 patients between 2 to less than 6 years of age, 61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The safety profile is generally consistent among paediatric patients aged 4 months and older and is also consistent with adult patients.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal"><span lang="EN-GB">The incidence of transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12 years), study 7 (patients aged 2 to less than 6 years), and study 8 (patients aged 6 to less than 24 months) are described in Table 3. </span><span lang="EN-GB">In the placebo controlled studies, the incidence of transaminase elevations were similar between treatment with ivacaftor (15.0%) and placebo</span>(14.6%)<span lang="EN-GB">Across all populations, </span>peak LFT <span lang="EN-GB">elevations </span>returned to baseline levels following interruption, and in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4). Cases suggestive of positive rechallenge were observed. In study 7 <span lang="EN-GB">ivacaftor was permanently discontinued in one patient. In study 8 </span><span lang="EN-GB">no patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in either cohort (see section 4.4 for management of elevated transaminases).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-bottom:12.0pt"><b><span lang="EN-GB">Table 3: Transaminase elevations in patients 4 months to &lt; 12 years treated with ivacaftor as monotherapy</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="margin-left:6.85pt;border-collapse:collapse;border:none"> <tr style="height:28.95pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="161"> <p class="MsoNormal"></p> </td> <td style="width:49.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">n</span></b></p> </td> <td style="width:80.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">% of Patients &gt; 3 x ULN </span></b></p> </td> <td style="width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">% of Patients &gt;5 x ULN</span></b></p> </td> <td style="width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">% of Patients &gt; 8 x ULN</span></b></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">6 to &lt;12 years</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">40</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">15.0%   (6)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2.5%   (1)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2.5%   (1)</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">2 to &lt;6 years</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">34</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">14.7%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">14.7%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">14.7%   (5)</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">12 to &lt;24 months</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">18</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">27.8%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11.1%   (2)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11.1%   (2)</span></p> </td> </tr> <tr style="height:13.7pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">6 to &lt;12 months</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">9.1%   (1)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> </tr> <tr style="height:13.7pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="161"> <p class="MsoNormal"><span lang="EN-GB">4 to &lt;6 months</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">6</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0.0%   (0)</span></p> </td> </tr> </table><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Reporting of suspected adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background: lightgrey">the national reporting system listed in </span><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="color:windowtext;background:lightgrey">Appendix V</span></a>.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9       Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"></p><p class="labeltext" style="page-break-after:avoid"><span style="font-size:11.0pt">No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Pharmacotherapeutic group: Other respiratory system products, ATC code: </span>R07AX02</p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB">Mechanism of action</span></u></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Ivacaftor is a potentiator of the CFTR protein, i.e., <i>in vitro</i> ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channelopen probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance). The <i>G970R </i>mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data). </span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal"><i><span lang="EN-GB">In vitro</span></i><span lang="EN-GB"> responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to <i>in vivo </i>pharmacodynamic response (e.g., sweat chloride) or clinical benefit. </span><span lang="EN-GB">The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Pharmacodynamic effects</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">In studies 1 and 2 in patients with the <i>G551D </i>mutation in one allele of the <i>CFTR</i> gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was 48 mmol/L [95% CI 51, 45] and 54 mmol/L [95% CI 62, 47], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.</span></p><p class="MsoNormal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal"><span lang="EN-GB">In study 5, part 1 in patients who had a non-<i>G551D</i> gating mutation in the <i>CFTR</i> gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of 49 mmol/L (95% CI 57, 41) through 8 weeks of treatment. However, in patients with the <i>G970R</i><i>CFTR</i> mutation, the mean (SD) absolute change in sweat chloride at week 8 was 6.25 (6.55) mmol/L. Similar results to part 1 were seen in part 2 of the study. At the 4week followup visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pretreatment levels.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In study 6 in patients aged 6 years or older with CF who had an <i>R117H</i> mutation in the <i>CFTR</i> gene, the treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment was 24 mmol/L (95% CI 28, 20). In subgroup analyses by age, the treatment difference was 21.87 mmol/L (95% CI: 26.46, 17.28) in patients aged 18 years or older, and 27.63 mmol/L (95% CI: 37.16, 18.10) in patients aged 611 years. Two patients 12 to 17 years of age were enrolled in this study.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In study 7 in patients aged 2 to less than 6 years with a gating mutation on at least 1 allele of the <i>CFTR</i> gene administered either 50 mg or 75 mg of ivacaftor twice daily, the mean absolute change from baseline in sweat chloride was 47 mmol/L (95% CI 58, 36) at week 24.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In study 8 in patients with CF aged less than 24 months, the mean absolute change from baseline in sweat chloride was -65.1 mmol/L (95% CI 74.1, 56.0) at week 24. Results were consistent in the 12 months to less than 24 months, 6 months to less than 12 months, and 4 months to less than 6 months age cohorts.</span></p><p class="MsoNormal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Clinical efficacy and safety</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Study 1 and 2: studies in patients with CF with G551D gating mutations</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">The efficacy of ivacaftor has been evaluated in two phase 3 randomised, doubleblind, placebocontrolled, multicentre studies of clinically stable patients with CF who had the <i>G551D</i> mutation in the <i>CFTR</i> gene on at least 1 allele and had FEV<sub>1</sub> </span><span style="font-family: SimSun"></span><span lang="EN-GB"> 40% predicted.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the <i>F508del</i> mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV<sub>1</sub> was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the <i>F508del</i> mutation in the second allele. At baseline, mean predicted FEV<sub>1</sub> was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV<sub>1</sub> less than 70% predicted at baseline.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV<sub>1</sub> through 24 weeks of treatment.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV<sub>1</sub> (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV<sub>1</sub> were rapid in onset (day 15) and durable through 48 weeks.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week 24 in patients with baseline predicted FEV<sub>1 </sub>greater than 90% in study 2 was 6.9 percentage points (3.8, 17.6).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The results for clinically relevant secondary endpoints are shown in Table 4.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Table 4: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2</span></b></p><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:98.82%;margin-left:5.45pt;border-collapse:collapse" width="98%"> <thead> <tr style="height:10.5pt"> <td rowspan="2" style="width:27.12%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="bottom" width="27%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Endpoint</span></b></p> </td> <td colspan="2" style="width:34.82%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="34%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Study 1</span></b></p> </td> <td colspan="2" style="width:38.06%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Study 2</span></b></p> </td> </tr> <tr style="height:28.25pt"> <td style="width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Treatment difference<sup>a</sup></span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">(95% CI)</span></b></p> </td> <td style="width:14.64%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><i><span lang="EN-GB">P </span></i><span lang="EN-GB">value</span></b></p> </td> <td style="width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Treatment difference<sup>a</sup></span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">(95% CI)</span></b></p> </td> <td style="width:17.88%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"><b><i><span lang="EN-GB">P </span></i><span lang="EN-GB">value</span></b></p> </td> </tr> </thead> <tr style="height:10.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Mean absolute change from baseline in CFQ-R</span></b><sup><span lang="EN-GB">b</span></sup><b><span lang="EN-GB"> respiratory domain score   (points)</span></b><sup><span lang="EN-GB">c</span></sup></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Through week   24</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">8.1</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(4.7, 11.4)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">6.1</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.4, 13.5)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.1092</span></p> </td> </tr> <tr style="height:18.85pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Through week   48</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">8.6</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(5.3, 11.9)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">5.1</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.6, 11.8)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.1354</span></p> </td> </tr> <tr style="height:9.95pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Relative risk of pulmonary exacerbation</span></b></p> </td> </tr> <tr style="height:10.5pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Through week 24</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.40</span><sup><span lang="EN-GB">d</span></sup></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0016</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">NA</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr style="height:9.95pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Through week 48</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.46<sup>d</sup></span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0012</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">NA</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr style="height:10.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Mean absolute change from baseline in body weight (kg)</span></b></p> </td> </tr> <tr style="height:18.85pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At week   24</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">2.8</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.8, 3.7)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">1.9</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.9, 2.9)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0004</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At week   48</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">2.7</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.3, 4.1)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">2.8</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(1.3, 4.2)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0002</span></p> </td> </tr> <tr style="height:15.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Mean absolute change from baseline in BMI (kg/m<sup>2</sup>)</span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At week 24</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.94</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.62, 1.26)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.81</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.34, 1.28)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0008</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At week 48</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.93</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.48, 1.38)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">1.09</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.51, 1.67)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0003</span></p> </td> </tr> <tr style="height:15.05pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.05pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Mean change from baseline in zscores</span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Weightforage   zscore at week 48<sup>e</sup></span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.33</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.04, 0.62)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.0260</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.39</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.24, 0.53)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">&lt; 0.0001</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">BMIforage zscore at week 48<sup>e</sup></span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.33</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">(0.002, 0.65)</span></p> </td> <td style="width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.0490</span></p> </td> <td style="width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="20%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">0.45</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">(0.26, 0.65)</span></p> </td> <td style="width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">&lt; 0.0001</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:9.0pt">CI: confidence interval; NA: not analysed due to low incidence of events </span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">a</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Treatment difference = effect of ivacaftor  effect of placebo</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">b</span></sup><span lang="EN-GB" style="font-size:9.0pt">     CFQ-R: Cystic Fibrosis Questionnaire-Revised is a disease-specific, health-related quality-of-life measure for CF.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">c</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Study 1 data were pooled from CFQ-R for adults/adolescents and CFQ-R for children 12 to 13 years of age; Study 2 data were obtained from CFQ-R for children 6 to 11 years of age.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">d</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Hazard ratio for time to first pulmonary exacerbation</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">e</span></sup><span lang="EN-GB" style="font-size:9.0pt">     In subjects under 20 years of age (CDC growth charts)</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Study 5: study in patients with CF with non-G551D gating mutations</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Study 5 was a phase 3, twopart, randomised, doubleblind, placebo-controlled, crossover study (part 1) followed by a 16week openlabel extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a <i>G970R</i> or non<i>G551D</i> gating mutation in the <i>CFTR</i> gene (<i>G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P</i> or<i> G1349D</i>).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fat-containing food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4- to 8week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to the part 1 placebo/ivacaftor treatment sequence and 16 weeks for patients randomised to part 1 ivacaftor/placebo treatment sequence.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Thirty-nine patients (mean age 23 years) with baseline FEV<sub>1</sub> </span><span style="font-family:SimSun"></span><span lang="EN-GB">40% predicted (mean FEV<sub>1</sub> 78% predicted [range: 43% to 119%]) were enrolled. Sixtytwo percent (24/39) of them carried the <i>F508del</i>-<i>CFTR</i> mutation in the second allele. A total of 36 patients continued into part 2 (18 per treatment sequence).</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In part 1 of study 5, the mean FEV<sub>1</sub> percent predicted at baseline in placebo-treated patients was 79.3% while in ivacaftortreated patients this value was 76.4%. The mean overall postbaseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week 8 in percent predicted FEV<sub>1</sub> (primary efficacy endpoint) was 7.5% in the ivacaftor period and 3.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) </span><span lang="EN-GB">(P &lt; 0.0001).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQR through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV<sub>1</sub> at week 8) is shown in Table 5. Based on clinical (percent predicted FEV<sub>1</sub>) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the <i>G970R</i> mutation could not be established.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="EN-GB">Table 5: Effect of ivacaftor for efficacy variables in the overall population and for specific <i>CFTR</i> mutations</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:454.0pt;margin-left:5.35pt;border-collapse:collapse;border:none" width="605"> <tr> <td colspan="2" style="width:147.75pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="197"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Absolute change in percent   predicted FEV<sub>1</sub></span></b></p> </td> <td colspan="2" style="width:152.5pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="203"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">BMI</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">(kg/m<sup>2</sup>)</span></b></p> </td> <td style="width:153.75pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">CFQ-R respiratory domain score   (points)</span></b></p> </td> </tr> <tr> <td colspan="2" style="width:147.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="197"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Through week 8</span></b></p> </td> <td colspan="2" style="width:152.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="203"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">At week 8</span></b></p> </td> <td style="width:153.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Through week 8</span></b></p> </td> </tr> <tr> <td colspan="5" style="width:454.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="605"> <p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">All patients (N = 39)</span></p> <p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Results shown as mean (95% CI) change from baseline ivacaftor vs.   placebo-treated patients:</span></p> </td> </tr> <tr> <td colspan="2" style="width:147.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="197"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">10.7 (7.3, 14.1)</span></p> </td> <td colspan="2" style="width:152.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="203"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.66 (0.34, 0.99)</span></p> </td> <td style="width:153.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">9.6 (4.5, 14.7)</span></p> </td> </tr> <tr style="height:13.4pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal;text-autospace:none"><b><span lang="EN-GB">Patients grouped under mutation types (n)</span></b></p> <p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Results shown as mean (minimum, maximum) change from baseline for   ivacaftor-treated patients <br/>   at week 8*:</span></p> </td> </tr> <tr style="height:13.4pt"> <td rowspan="2" style="width:18.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="bottom" width="18%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   text-autospace:none"><b><span lang="EN-GB">Mutation (n)</span></b></p> </td> <td colspan="2" style="width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="40%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   text-autospace:none"><b><span lang="EN-GB">Absolute change in sweat chloride   (mmol/L)</span></b></p> </td> <td colspan="2" style="width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="40%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   text-autospace:none"><b><span lang="EN-GB">Absolute change in percent predicted   FEV<sub>1 </sub>(percentage points)</span></b></p> </td> </tr> <tr style="height:13.4pt"> <td colspan="2" style="width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="40%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   text-autospace:none"><b><span lang="EN-GB">At week 8</span></b></p> </td> <td colspan="2" style="width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt" valign="top" width="40%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   text-autospace:none"><b><span lang="EN-GB">At week 8</span></b></p> </td> </tr> <tr style="height:88.5pt"> <td style="width:18.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:88.5pt" valign="top" width="18%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   text-autospace:none"><i><span lang="PT">G1244E</span></i><span lang="PT"> (5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><i><span lang="PT">G1349D</span></i><span lang="PT"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><i><span lang="PT">G178R</span></i><span lang="PT"> (5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><i><span lang="PT">G551S</span></i><span lang="PT"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><i><span lang="PT">G970R<sup>#</sup></span></i><span lang="PT"> (4)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><i><span lang="EN-GB">S1251N </span></i><span lang="EN-GB">(8)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><i><span lang="EN-GB">S1255P</span></i><span lang="EN-GB"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><i><span lang="EN-GB">S549N</span></i><span lang="EN-GB"> (6)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   text-autospace:none"><i><span lang="EN-GB">S549R</span></i><span lang="EN-GB">   (4)</span></p> </td> <td colspan="2" style="width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:88.5pt" valign="top" width="40%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-55 (-75, -34)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-80 (-82, -79)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-53 (-65, -35)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-68<sup><span style="position:relative;top:-3.0pt"></span></sup></span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-6 (-16, -2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-54 (-84, -7)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-78 (-82, -74)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-74 (-93, -53)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">-61<span style="position:relative;top:-3.0pt"></span> (-71, -54)</span></p> </td> <td colspan="2" style="width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:88.5pt" valign="top" width="40%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">8 (-1, 18)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">20 (3, 36)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">8 (-1, 18)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">3<sup><span style="position:relative;top:-3.0pt"></span></sup></span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">3 (-1, 5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">9 (-20, 21)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">3 (-1, 8)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">11 (-2, 20)</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">5 (-3, 13)</span></p> </td> </tr> <tr height="0"> <td style="border:none" width="113"></td> <td style="border:none" width="123"></td> <td style="border:none" width="123"></td> <td style="border:none" width="123"></td> <td style="border:none" width="124"></td> </tr> </table><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">*</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Statistical testing was not performed due to small numbers for individual mutations.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt"></span></sup><span lang="EN-GB" style="font-size:9.0pt">     Reflects results from the one patient with the <i>G551S</i> mutation with data at the 8-week time point.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt"></span></sup><span lang="EN-GB" style="font-size:9.0pt">    n = 3 for the analysis of absolute change in sweat chloride.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">#        </span></sup><span lang="EN-GB" style="font-size:9.0pt">Causes a splicing defect resulting in little-to-no CFTR protein at the cell surface</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV<sub>1</sub> following 16 weeks (patients randomised to the ivacaftor/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the followup visit 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1 </sub>from<sub> </sub>part 2 week 16 was 5.9% (9.4%). For patients randomised to the placebo/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV<sub>1</sub> after the additional 16 weeks of treatment with ivacaftor. At the follow up visit 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1</sub> from part 2 week 16 was 7.4% (5.5%).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Study 3: study in patients with CF with the F508del mutation in the CFTR gene</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Study 3 (part A) was a 16week, 4:1 randomised, doubleblind, placebocontrolled, parallelgroup phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the <i>F508del</i> mutation in the <i>CFTR</i> gene and who had FEV<sub>1</sub>  40% predicted.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The mean absolute change from baseline through week 16 in percent predicted FEV<sub>1</sub> (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and 0.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI 0.6, 4.1); this difference was not statistically significant (P = 0.15).</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Study 4: open-label extension study</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">In study 4, patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo/ivacaftor group and at least 144 weeks for patients in the ivacaftor/ivacaftor group.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">One hundred and fortyfour (144) patients from study 1 were rolled over in study 4, 67 in the placebo/ivacaftor group and 77 in the ivacaftor/ivacaftor group. Fortyeight (48) patients from study 2 were rolled over in study 4, 22 in the placebo/ivacaftor group and 26 in the ivacaftor/ivacaftor group.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Table</span><span lang="EN-GB">6 shows the results of the mean (SD) absolute change in percent predicted FEV<sub>1</sub> for both groups of patients. For patients in the placebo/ivacaftor group baseline percent predicted FEV<sub>1</sub> is that of study 4 while for patients in the ivacaftor/ivacaftor group the baseline value is that of studies</span><span lang="EN-GB">1 and 2.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-bottom:6.0pt;line-height:normal;page-break-after: avoid"><b><span lang="EN-GB">Table 6: Effect of ivacaftor on percent predicted FEV</span></b><sub><span lang="EN-GB">1</span></sub><b><span lang="EN-GB"> in study 4</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:5.4pt;border-collapse:collapse;border:none"> <tr> <td rowspan="2" style="width:24.72%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="bottom" width="24%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Original study and treatment group</span></b></p> </td> <td rowspan="2" style="width:27.72%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="bottom" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Duration of ivacaftor treatment (weeks)</span></b></p> </td> <td colspan="2" style="width:47.56%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="47%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Absolute change from baseline in   percent predicted FEV<sub>1 </sub>(percentage points)</span></b></p> </td> </tr> <tr> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">N</span></b></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Mean (SD)</span></b></p> </td> </tr> <tr> <td colspan="4" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Study 1</span></b></p> </td> </tr> <tr> <td rowspan="2" style="width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="24%"> <p class="MsoNormal" style="margin-left:28.35pt;line-height:normal"><b><span lang="EN-GB">Ivacaftor</span></b></p> </td> <td style="width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">48<sup>*</sup></span></p> </td> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">77</span></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">9.4 (8.3)</span></p> </td> </tr> <tr> <td style="width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">144</span></p> </td> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">72</span></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">9.4 (10.8)</span></p> </td> </tr> <tr> <td rowspan="2" style="width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="24%"> <p class="MsoNormal" style="margin-left:28.35pt;line-height:normal"><b><span lang="EN-GB">Placebo</span></b></p> </td> <td style="width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0<sup>*</sup></span></p> </td> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">67</span></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">1.2 (7.8)<sup><span style="position:relative;top:-3.0pt"></span></sup></span></p> </td> </tr> <tr> <td style="width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">96</span></p> </td> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">55</span></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">9.5 (11.2)</span></p> </td> </tr> <tr> <td colspan="4" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="100%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Study 2</span></b></p> </td> </tr> <tr> <td rowspan="2" style="width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="24%"> <p class="MsoNormal" style="margin-left:28.35pt;line-height:normal"><b><span lang="EN-GB">Ivacaftor</span></b></p> </td> <td style="width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">48<sup>*</sup></span></p> </td> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">26</span></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">10.2 (15.7)</span></p> </td> </tr> <tr> <td style="width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">144</span></p> </td> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">25</span></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">10.3 (12.4)</span></p> </td> </tr> <tr> <td rowspan="2" style="width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="24%"> <p class="MsoNormal" style="margin-left:28.35pt;line-height:normal"><b><span lang="EN-GB">Placebo</span></b></p> </td> <td style="width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0<sup>*</sup></span></p> </td> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">22</span></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.6 (10.1)<sup><span style="position:relative;top:-3.0pt"></span></sup></span></p> </td> </tr> <tr> <td style="width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">96</span></p> </td> <td style="width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="14%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">21</span></p> </td> <td style="width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="32%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">10.5 (11.5)</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in"><sup><span lang="EN-GB" style="font-size:9.0pt">*</span></sup><span lang="EN-GB" style="font-size:9.0pt">     Treatment occurred during blinded, controlled, 48-week phase 3 study.</span></p><p class="MsoNormal" style="margin-left:.2in;text-indent:-.2in;line-height:normal"><sup><span lang="EN-GB" style="font-size:9.0pt"></span></sup><span lang="EN-GB" style="font-size:9.0pt">     Change from prior study baseline after 48 weeks of placebo treatment.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">When the mean (SD) absolute change in percent predicted FEV<sub>1</sub> is compared from study 4 baseline for patients in the ivacaftor/ivacaftor group (n</span><span lang="EN-GB"> = </span><span lang="EN-GB">72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV<sub>1</sub> was 0.0% (9.05), while for patients in the ivacaftor/ivacaftor group (n</span><span lang="EN-GB"> = </span><span lang="EN-GB">25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor/ivacaftor group maintained the improvement seen at </span><span lang="EN-GB">week</span><span lang="EN-GB"> 48 of the initial study (</span><span lang="EN-GB">day</span><span lang="EN-GB"> 0 through </span><span lang="EN-GB">week</span><span lang="EN-GB"> 48) in percent predicted FEV<sub>1</sub> through </span><span lang="EN-GB">week</span><span lang="EN-GB"> 144. There were no additional improvements in study 4 (</span><span lang="EN-GB">week</span><span lang="EN-GB"> 48 through </span><span lang="EN-GB">week</span><span lang="EN-GB"> 144).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal"><span lang="EN-GB">For patients in the placebo/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events/year across </span><span lang="EN-GB">day</span><span lang="EN-GB"> 1 to </span><span lang="EN-GB">week</span><span lang="EN-GB"> 48, and 0.67 events/year across </span><span lang="EN-GB">weeks</span><span lang="EN-GB"> 48 to 96). For patients in the ivacaftor/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events/year across </span><span lang="EN-GB">day</span><span lang="EN-GB"> 1 to </span><span lang="EN-GB">week</span><span lang="EN-GB"> 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events/year across </span><span lang="EN-GB">day</span><span lang="EN-GB"> 1 to </span><span lang="EN-GB">week</span><span lang="EN-GB"> 48 and 0.77 events/year across </span><span lang="EN-GB">weeks</span><span lang="EN-GB"> 48 to 96.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">For patients who rolled over from study 2 the number of events was, overall, low.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i>Study 6: study in patients with CF with an R117H mutation in the CFTR gene</i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid">Study 6 evaluated 69 patients who were 6 years of age or older; 53 (76.8%) patients had the <i>F508del</i> mutation in the second allele. The confirmed <i>R117H </i>polyT variant was <i>5T </i>in 38 patientsand <i>7T </i>in 16 patients. At baseline, mean predicted FEV<sub>1</sub> was 73% (range: 32.5% to 105.5%) and mean age was 31 years (range: 6 to 68 years). The mean absolute change from baseline through week 24 in percent predicted FEV<sub>1</sub> (primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 2.1 percentage points (95% CI 1.1, 5.4).</p><p class="MsoNormal"> </p><p class="MsoNormal">A preplanned subgroup analysis was conducted in patients 18 years and older (26 patients on placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in percent predicted FEV<sub>1</sub> through week 24 of 4.5 percentage points in the ivacaftor group versus 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 5.0 percentage points (95% CI 1.1, 8.8).</p><p class="MsoNormal"> </p><p class="MsoNormal">In a subgroup analysis in patients with a confirmed <i>R117H5T </i>genetic variant, the difference in the mean absolute change from baseline through week24 in percent predicted FEV<sub>1</sub> between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a confirmed <i>R117H7T </i>genetic variant, the treatment difference between ivacaftor and placebo was 0.2% (95% CI 8.1, 8.5).</p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">For secondary efficacy variables, no treatment differences were observed for ivacaftor versus placebo in absolute change from baseline in BMI at week 24 or time to first pulmonary exacerbation. Treatment differences were observed in absolute change in CFQR respiratory domain score through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from baseline in sweat chloride (see Pharmacodynamic effects).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Study 7: study in paediatric patients </span><span lang="EN-GB">with CF </span></i><i><span lang="EN-GB">aged 2 to less than 6</span><span lang="EN-GB"> years with G551D or another gating mutation</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The pharmacokinetic profile, safety and efficacy of ivacaftor in 34 patients aged 2 to less than 6 years with CF who had a <i>G551D</i>, <i>G1244E</i>, <i>G1349D</i>,<i> G178R</i>,<i> G551S</i>,<i> S1251N</i>,<i> S1255P</i>,<i> S549N</i> or<i> S549R</i>mutation in the <i>CFTR</i> gene were assessed in a 24week uncontrolled study with ivacaftor (patients weighing less than 14 kg received ivacaftor 50 mg and patients weighing 14 kg or more received ivacaftor 75 mg). Ivacaftor was administered orally every 12 hours with fatcontaining food in addition to their prescribed CF therapies.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Patients in study 7 were aged 2 to less than 6 years (mean age 3 years). Twentysix patients out of the 34 enrolled (76.5%) had a <i>CFTR</i> genotype <i>G551D/F508del</i> with only 2 patients with a non<i>G551D</i> mutation (<i>S549N</i>). The mean (SD) sweat chloride at baseline (n = 25) was 97.88 mmol/L (14.00). The mean (SD) faecal elastase1 value at baseline (n = 27) was 28 g/g (95).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The primary endpoint of safety was evaluated through week 24 (see section 4.8). Secondary and exploratory efficacy endpoints evaluated were absolute change from baseline in sweat chloride through 24 weeks of treatment, absolute change from baseline in weight, body mass index (BMI) and stature (supported by weight, BMI and stature z-scores) at 24 weeks of treatment, and measures of pancreatic function such as faecal elastase1. Data on percent predicted FEV<sub>1</sub> (exploratory endpoint) were available for 3 patients in the ivacaftor 50 mg group and 17 patients in the 75 mg dosing group.</span></p><p class="MsoNormal" style="line-height:normal"><s><span lang="EN-GB"></span></s></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The mean (SD) overall (both ivacaftor dosing groups combined) absolute change from baseline in BMI at week 24 was 0.32 kg/m<sup>2</sup> (0.54) and the mean (SD) overall change in BMIforage zscore was 0.37 (0.42). The mean (SD) overall change in stature-for-age z-score was 0.01 (0.33). The mean (SD) overall change from baseline in faecal elastase1 (n = 27) was 99.8 g/g (138.4). Six patients with initial levels below 200 g/g achieved, at week 24, a level of  200 g/g. The mean (SD) overall change in percent predicted FEV<sub>1 </sub>from baseline at week 24 (exploratory endpoint) was 1.8 (17.81).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Study 8: study in paediatric patients </span><span lang="EN-GB">with CF </span></i><i><span lang="EN-GB">aged less than 24 months</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The pharmacokinetic profile, safety, and efficacy of ivacaftor in patients with CF aged 6 months to less than 24 months were assessed in a completed cohort of patients in an on-going 24week, openlabel, phase 3 clinical study in patients aged less than 24 months (study 8).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Part B of study 8 enrolled 19 patients aged 12 months to less than 24 months (mean age 15.2 months at baseline), with 18 patients completing the 24week treatment period, 11 patients aged 6 months to less than 12 months (mean age 9.0 months at baseline) with all 11 patients completing the 24week treatment period, and 6 patients aged 4 months to less than 6 months (mean age 4.5 months at baseline) with all 6 patients completing the 24week treatment period. Patients received ivacaftor 25 mg, 50 mg or 75 mg according to their age and weight at each study visit (see section 4.2). Ivacaftor was administered orally every 12 hours with fat</span><span lang="EN-GB" style='font-family:"MS Mincho"'></span><span lang="EN-GB">containing food. Patients continued on their prescribed standardofcare CF therapies.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In part B of study 8 the primary endpoint of safety was evaluated through 24 weeks (see section 4.8). Secondary endpoints were evaluation of pharmacokinetics and the absolute change from baseline in sweat chloride through 24 weeks of treatment (see Pharmacodynamic effects). Tertiary endpoints included efficacy measures such as faecal elastase1 and growth parameters.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">For patients aged 4 months to less than 24 months, with both baseline and week 24 values available, mean (SD) weightforage, lengthforage, and weightforlength zscores are provided in Table 7.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after: avoid"><b><span lang="EN-GB">Table 7: Effect of ivacaftor on growth parameters in patients aged 4 months to less than 24 months with baseline and week 24 values</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="TableGrid1" style="border-collapse:collapse;border:none" width="601"> <tr> <td rowspan="2" style="width:126.9pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="169"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Parameter</span></b></p> </td> <td rowspan="2" style="width:.75in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Number of patients</span></b></p> </td> <td colspan="2" style="width:1.75in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" width="168"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Baseline</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td colspan="2" style="width:2.0in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" width="192"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><b><span lang="EN-GB">Absolute change at week 24</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr> <td style="width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Mean</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">(SD)</span></b></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Median</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">(min, max)</span></b></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Mean</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">(SD)</span></b></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Median</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">(min, max)</span></b></p> </td> </tr> <tr> <td style="width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Weightforage   zscore</span></p> </td> <td style="width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">35</span></p> </td> <td style="width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.17 (0.85)</span></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.20</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">[-1.92, 1.79]</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.33</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.53)</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.26</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">[-0.54, 1.63]</span></p> </td> </tr> <tr> <td style="width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Lengthforage   zscore</span></p> </td> <td style="width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">34</span></p> </td> <td style="width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.06 (1.03) </span></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.12</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">[-1.99, 2.79]</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.32</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">(0.92)</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">0.47</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">[-1.81, 3.38]</span></p> </td> </tr> <tr> <td style="width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Weightforlength   zscore</span></p> </td> <td style="width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="72"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">34</span></p> </td> <td style="width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="color:black">0.24 (1.01)</span></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="color:black">0.26</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="color:black">[-1.72, 2.16]</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="color:black">0.24</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="color:black">(0.98)</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="color:black">0.29</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="color:black">[-2.04, 2.22]</span></p> </td> </tr> </table><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In patients aged 4 months to less than 24 months, with both baseline and week 24 values available, 18 patients were pancreatic insufficient at baseline (defined as faecal elastase-1 &lt; 200 g/g) with mean (SD) faecal elastase1 values at baseline and week 24 of 25.5 g/g (27.6) and 253.6 g/g (128.3), respectively (mean [SD] absolute change 228.41 g/g [128.3]). Results were consistent in the 12 months to less than 24 months, 6 months to less than 12 months, and 4 months to less than 6 months age cohorts.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis (see section 4.2 for information on paediatric use).</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2       Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid">The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.</p><p class="MsoNormal" style="line-height:normal"> </p><p class="MsoNormal" style="line-height:normal">After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean ( SD) for AUC and C<sub>max</sub> were 10600 (5260) ng*hr/mL and 768 (233) ng/mL, respectively. After every 12hour dosing, steady-state plasma concentrations of ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.</p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Absorption</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food the exposure of ivacaftor increased approximately 2.5- to 4fold. Therefore, ivacaftor should be administered with fatcontaining food. The median (range) t<sub>max </sub>is approximately 4.0 (3.0; 6.0) hours in the fed state.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Ivacaftor granules (2 x 75</span><span lang="EN-GB"> mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC<sub>0-</sub> and 0.918 (0.750, 1.12) for C<sub>max</sub>. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB">Distribution</span></u></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells. After oral administration of ivacaftor 150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean ( SD) apparent volume of distribution was 353 L (122) .</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Biotransformation</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Ivacaftor is extensively metabolised in humans. <i>In vitro</i> and <i>in vivo</i> data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately onesixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than onefiftieth the potency of ivacaftor and is not considered pharmacologically active.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The effect of the CYP3A4*22 heterozygous genotype on ivacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose adjustment of ivacaftor is considered necessary. The effect of CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Elimination</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal halflife was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean (SD) CL/F for a single 150 mg dose was 17.3 (8.4) L/hr in healthy subjects.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Linearity/nonlinearity</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 25 mg to 250 mg.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Special populations</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had similar ivacaftor C<sub>max</sub> (mean [ SD] of 735 [331] ng/mL) but an approximately two-fold increase in ivacaftor AUC<sub>0-</sub></span><sub><span style="font-family:SimSun"></span></sub><span lang="EN-GB"> (mean [ SD] of 16800 [6140] ng*hr/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steady-state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady-state C<sub>min</sub> values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. Based on these results, a modified regimen of Kalydeco monotherapy is recommended for patients with moderate hepatic impairment (see section 4.2)</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The impact of severe hepatic impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of ivacaftor have not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment. The use of Kalydeco in patients with severe hepatic impairment is therefore not recommended unless the benefits outweigh the risks (see section 4.2 and section 4.4).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No dose adjustment is considered necessary for patients with mild hepatic impairment.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment. In a human pharmacokinetic study, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No dose adjustments are recommended for mild and moderate renal impairment. However, caution is recommended when administering ivacaftor to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or end-stage renal disease (see sections 4.2 and 4.4).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Race</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Race had no clinically meaningful effect on the PK of ivacaftor in white (n = 379) and non-white (n = 29) patients based on a population PK analysis.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Gender</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">The pharmacokinetic parameters of ivacaftor are similar in males and females.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Elderly</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Clinical studies of ivacaftor as monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 8. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-bottom:6.0pt;line-height:normal"><b><span lang="EN-GB">Table 8: Mean (SD) ivacaftor exposure by age group</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.66%;margin-left:5.45pt;border-collapse:collapse;border:none" width="99%"> <thead> <tr style="height:13.7pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:13.7pt" width="56%"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Age group</span></b></p> </td> <td style="width:15.24%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" width="15%"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Dose</span></b></p> </td> <td style="width:12.34%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" width="12%"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">C<sub>min, ss</sub> (ng/mL)</span></b></p> </td> <td style="width:15.68%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" width="15%"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="PT">AUC</span><sub><span lang="EN-GB"></span></sub></b><b><sub><span lang="PT">,ss</span></sub></b><b><span lang="PT"> (ng*h/mL)</span></b></p> </td> </tr> </thead> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">4 months to less than 6 months (</span><span style="font-family:SimSun"></span><span lang="EN-GB">5 kg)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">25 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">371 (183)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">6480 (2520)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">6 months to less than 12 months   (5 kg to &lt; 7 kg) <sup>*</sup></span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">25 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">336</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">5410</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">6 months to less than 12 months   (7 kg to &lt; 14 kg)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">50 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">508 (252)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">9140 (4200)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">12 months to less than   24 months (7 kg to &lt; 14 kg)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">50 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">440 (212)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">9050 (3050)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">12 months to less than   24 months (</span><span style="font-family:SimSun"></span><span lang="EN-GB"> 14 kg to &lt; 25 kg)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">75 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">451 (125)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">9600 (1800)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">2- to 5-year-olds (&lt; 14 kg)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">50 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">577 (317)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">10500 (4260)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">2- to 5-year-olds ( 14 kg   to &lt; 25 kg)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">75 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">629 (296)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">11300 (3820)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" width="56%"> <p class="MsoNormal"><span lang="EN-GB">6- to 11-year-olds <sup></sup> ( 14 kg   to &lt; 25 kg)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">75 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">641 (329)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">10760 (4470)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">6- to 11-year-olds <sup></sup> ( 25 kg)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">150 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">958 (546)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">15300 (7340)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">12- to 17-year-olds</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">150 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">564 (242)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">9240 (3420)</span></p> </td> </tr> <tr style="height:15.15pt"> <td style="width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="EN-GB">Adults ( 18 years old)</span></p> </td> <td style="width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">150 mg q12h</span></p> </td> <td style="width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="12%"> <p class="MsoNormal"><span lang="EN-GB">701 (317)</span></p> </td> <td style="width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt" valign="top" width="15%"> <p class="MsoNormal"><span lang="EN-GB">10700 (4100)</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">*</span></sup><sup> </sup><span style="font-size:9.0pt">Values based on data from a single patient; standard deviation not reported.</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid"><sup><span lang="EN-GB" style="font-size:9.0pt;position:relative; top:-3.0pt"></span></sup><span lang="EN-GB" style="font-size:9.0pt">     Exposures in 6 to 11yearolds are predictions based on simulations from the population PK model using data obtained for this age group.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Pregnancy and fertility</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The NoObservedAdverseEffectLevel (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Peri and postnatal development</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Juvenile animal studies</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7week old rats, nor in 3.5 to 5month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Silica, colloidal anhydrous</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Croscarmellose sodium</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Hypromellose acetate succinate</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Lactose monohydrate</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Magnesium stearate</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Mannitol</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Sucralose</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="IT">Sodium laurilsulfate (E487)</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not applicable.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3       Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">3 years.</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Once mixed, the mixture has been shown to be stable for one hour.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">This medicinal product does not require any special storage conditions.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">The granules are packed in a Biaxially Oriented Polyethylene Terephthalate/Polyethylene/Foil/Polyethylene (BOPET/PE/Foil/PE) sachet.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Pack size of 56 sachets (contains 4 individual wallets with 14 sachets per wallet)</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Vertex Pharmaceuticals (Ireland) Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">28-32 Pembroke Street Upper</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dublin 2, D02 EK84</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Ireland</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">EU/1/12/782/003</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">EU/1/12/782/004</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">EU/1/12/782/006</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Date of first authorisation: 23 July 2012</span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Date of latest renewal: 28 April 2017</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency <u>http://www.ema.europa.eu.</u></span></p><u><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></u><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>